-
1Academic Journal
Authors: Шухратиллоевна , Тошназарова Нодира
Source: World of Medicine : Journal of Biomedical Sciences; Vol. 2 No. 4 (2025): World of Medicine : Journal of Biomedical Sciences; 14-21 ; 2960-9356
Subject Terms: ревматоидный артрит, метотрексат, генно-инженерные биологические препараты, лечение, ремиссия, эффективность, безопасность
File Description: application/pdf
-
2Academic Journal
Authors: A. V. Rudakova, Т. V. Korotaeva, А. В. Рудакова, Т. В. Коротаева
Source: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 17, No 4 (2024); 504-512 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 17, No 4 (2024); 504-512 ; 2070-4933 ; 2070-4909
Subject Terms: таргетные синтетические базисные противовоспалительные препараты, psoriatic arthritis, netakimab, biological disease-modifying antirheumatic drugs, targeted synthetic disease-modifying antirheumatic drugs, псориатический артрит, нетакимаб, генно-инженерные биологические препараты
File Description: application/pdf
Relation: https://www.pharmacoeconomics.ru/jour/article/view/1139/590; Псориаз артропатический. Псориатический артрит. Клинические рекомендации. 2024. URL: https://cr.minzdrav.gov.ru/view-cr/562_3 (дата обращения 25.11.2024).; Gladman D.D., Antoni C., Mease P., et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64 (Suppl. 2): ii14–7. https://doi.org/10.1136/ard.2004.032482.; Толкачева Д.Г., Младов В.В., Соколова В.Д. Эффективность генно-инженерных биологических и таргетных синтетических препаратов, зарегистрированных в России для терапии взрослых пациентов с активным псориатическим артритом: систематический обзор и сетевой метаанализ. Медицинские технологии. Оценка и выбор. 2021; 2: 51–66. https://doi.org/10.17116/medtech20214302151.; Румянцева Е.И., Железнякова И.А., Плахотник О.С. и др. Основные изменения в модели оплаты медицинской помощи по клиникостатистическим группам в Российской Федерации в 2024 году. Медицинские технологии. Оценка и выбор. 2024; 2: 10–21. https://doi.org/10.17116/medtech20244602110.; Lu C., Wallace B.I., Waljee A.K., et al. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta analysis. Semin Arthritis Rheum. 2019; 49 (3): 381–8. https://doi.org/10.1016/j.semarthrit.2019.06.001.; Ruyssen-Witrand A., Perry R., Watkins C., et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020; 6 (1): e001117. https://doi.org/10.1136/rmdopen-2019-001117.; Рудакова А.В., Толкачева Д.Г., Соколова В.Д. Фармакоэкономические аспекты терапии псориатического артрита среднетяжелой и тяжелой степени. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021; 14 (2): 116–23. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.095.; https://www.pharmacoeconomics.ru/jour/article/view/1139
-
3Academic Journal
Authors: A. V. Rudakova, I. Z. Gaydukova, А. В. Рудакова, И. З. Гайдукова
Source: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 17, No 4 (2024); 454-462 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 17, No 4 (2024); 454-462 ; 2070-4933 ; 2070-4909
Subject Terms: клинико-экономическая эффективность, radiographic axial spondyloarthritis, biological disease-modifying antirheumatic drugs, netakimab, clinical and economic effectiveness, аксиальный спондилоартрит рентгенологический, генно-инженерные биологические препараты, нетакимаб
File Description: application/pdf
Relation: https://www.pharmacoeconomics.ru/jour/article/view/1137/586; Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г. и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015; 53 (6): 657–60.; Гайдукова И.З., Мазуров В.И. Анкилозирующий спондилит. В кн.: Мазуров В.И. (ред.) Клиническая ревматология. 3-е изд. М.: Е-ното; 2021: 127–41.; Ramiro S., Nikiphorou E., Sepriano A., et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023; 82 (1): 19–34. https://doi.org/10.1136/ard-2022-223296.; Каратеев Д.Е., Лучихина Е.Л. Современное лечение спондилоартритов: фокус на нетакимаб. Терапевтический архив. 2024; 96 (5): 543–50. https://doi.org/10.26442/00403660.2024.05.202794.; Мешков А.Д., Воробьева Н.М., Остапенко В.С. и др. Опыт применения нетакимаба для лечения спондилоартритов в реальной клинической практике. Терапевтический архив. 2023; 95 (12): 1172–8. https://doi.org/10.26442/00403660.2023.12.202547.; Дубинина Т.В., Гайдукова И.З., Саблева Н.А. и др. Сравнительная оценка клинико-экономической эффективности ингибиторов интерлейкина 17 при лечении анкилозирующего спондилита. Научно-практическая ревматология. 2022; 60 (6): 594–601. https://doi.org/10.47360/1995-4484-2022-594-601.; Дубинина Т.В., Гайдукова И.З., Соколова В.Д. и др. Эффективность и безопасность генно-инженерных биологических препаратов для лечения анкилозирующего спондилита: систематический обзор и метаанализ препаратов, зарегистрированных в РФ. Научно-практическая ревматология. 2020; 58 (6): 646–57. https://doi.org/10.47360/1995-4484-2020-646-657.; Румянцева Е.И., Железнякова И.А., Плахотник О.С. и др. Основные изменения в модели оплаты медицинской помощи по клинико-статистическим группам в Российской Федерации в 2024 году. Медицинские технологии. Оценка и выбор. 2024; 2: 10–21. https://doi.org/10.17116/medtech20244602110.; https://www.pharmacoeconomics.ru/jour/article/view/1137
-
4Academic Journal
Contributors: The study was conducted as part of a research project, state assignment №1021051503137-7, Исследование выполнено в рамках научно-исследовательской работы, государственное задание №1021051503137-7
Source: Modern Rheumatology Journal; Том 19, № 2 (2025); 107-112 ; Современная ревматология; Том 19, № 2 (2025); 107-112 ; 2310-158X ; 1996-7012
Subject Terms: генно-инженерные биологические препараты, rheumatoid arthritis, spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, risk factors, biologic disease-modofying antirheumatic drugs, ревматоидный артрит, спондилоартрит, анкилозирующий спондилит, псориатический артрит, факторы риска
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1750/1594; Germano V, Cattaruzza MS, Osborn J, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticoster-oids and TNF- antagonists. J Transl Med. 2014 Mar 22:12:77. doi:10.1186/1479-5876-12-77.; Pinheiro FA, Souza DC, Sato EI. A Study of Multiple Causes of Death in Rheumatoid Arthritis. J Rheumatol. 2015 Dec;42(12): 2221-8. doi:10.3899/jrheum.150166. Epub 2015 Oct 15.; Choi IA, Lee JS, Song YW, Lee EY. Mortality, disability, and healthcare expenditure of patients with seropositive rheumatoid arthritis in Korea: A nationwide populationbased study. PLoS One. 2019 Jan 8;14(1): e0210471. doi:10.1371/journal.pone.0210471.; Aureal M, Seauve M, Laplane S, et al. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies. RMD Open. 2023 Sep;9(3):e003064. doi:10.1136/rmdopen-2023-003064.; Yamanaka H, Askling J, Berglind N, et al. Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open. 2017 Oct 10;3(2):e000498. doi:10.1136/rmdopen-2017-000498.; Thomas K, Lazarini A, Kaltsonoudis E, et al. Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Rheumatology (Oxford). 2021 May 14;60(5):2223-2230. doi:10.1093/rheumatology/keaa557.; Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012 Dec; 12(2):225-9. doi:10.1016/j.autrev.2012.06.008.; Atzeni F, Sarzi-Puttini P, Sebastiani M, et al. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. Clin Exp Rheumatol. 2019 Jul-Aug;37(4):649-655. Epub 2019 Feb 11.; Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019 Jun 9;5(1): e000935. doi:10.1136/rmdopen-2019-000935.; Wallis D, Thavaneswaran A, Haroon N, et al. Tumour necrosis factor in-hibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort. Rheumatology (Oxford). 2015 Jan;54(1): 152-6. doi:10.1093/rheumatology/keu255. Epub 2014 Aug 13.; Sharma C, Keen H. Ten-year retrospective review of the incidence of serious infections in patients on biologic disease modifying agents for rheumatoid arthritis in three tertiary hospitals in Western Australia. Intern Med J. 2019 Apr;49(4):519-525. doi:10.1111/imj.14109.; Burmester GR, Gordon KB, Rosenba um JT, et al. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Adv Ther. 2020 Jan;37(1):364-380. doi:10.1007/s12325-019-01145-8.; Dixon WG, Watson K, Lunt M, et al. British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006 Aug;54(8):2368-76. doi:10.1002/art.21978.; Taylor PC, Atzeni F, Balsa A, et al. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med. 2021 Feb 1;10(3):509. doi:10.3390/jcm10030509.; Accortt NA, Lesperance T, Liu M, et al. Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018 May;70(5):679-684. doi:10.1002/acr.23426.; Moura CS, Rahme E, Maksymowych WP, et al. Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis. Scand J Rheumatol. 2019 Mar;48(2): 121-127. doi:10.1080/03009742.2018.1470253. Epub 2018 Aug 16.; Roubille C, Coffy A, Rincheval N, et al. Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 2021 Aug 2;60(8):3738-3746. doi:10.1093/rheumatology/keaa850.; George MD, Baker JF, Winthrop K, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a Cohort study. Ann Intern Med. 2020 Dec 1;173(11):870-878. doi:10.7326/M20-1594. Epub 2020 Sep 22.; Atzeni F, Masala IF, di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Curr Opin Rheumatol. 2017 Jul;29(4):323-330. doi:10.1097/BOR.0000000000000389.; Hashimoto A, Suto S, Horie K, et al. Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis. Int J Rheumatol. 2017:2017:6730812. doi:10.1155/2017/6730812. Epub 2017 Oct 18.; Quartuccio L, Zabotti A, Del Zotto S, et al. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. J Adv Res. 2018 Sep 19;15:87-93. doi:10.1016/j.jare.2018.09.003.; Frisell T, Bower H, Morin M, et al. Safety of biological and targeted synthetic diseasemodifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann Rheum Dis. 2023 May;82(5):601-610. doi:10.1136/ard-2022-223762.; Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017 Jun;76(6):1101-1136. doi:10.1136/annrheumdis-2016-210708.; Liao H, Zhong Z, Liu Z, Zou X. Compa rison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis. 2017 Feb;20(2):161-168. doi:10.1111/1756-185X.12970.; Sepriano A, Kerschbaumer A, Bergstra SA, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023 Jan;82(1):107-118. doi:10.1136/ard-2022-223357.; Chen SK, Liao KP, Liu J, et al. Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study. Arthritis Care Res (Hoboken). 2020 Jan;72(1): 9-17. doi:10.1002/acr.23824. Epub 2019 Nov 29.; Chen HH, Lin CH, Wang CY, et al. Association of hospitalised infection with socioeconomic status in patients with rheumatoid arthritis receiving biologics or tofacitinib: a population-basedcohort study. Front Med (Lausanne). 2021 Jul 12;8:696167. doi:10.3389/fmed.2021.696167.; Grøn KL, Glintborg B, Nørgaard M, et al. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study. Rheumatology (Oxford). 2020 Aug 1; 59(8):1949-1956. doi:10.1093/rheumatology/kez530.; Jeon HL, Kim SC, Park SH, Shin JY. The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea. Semin Arthritis Rheum. 2021 Oct;51(5): 989-995. doi:10.1016/j.semarthrit.2021.07.004. Epub 2021 Jul 8.; Kremer JM, Bingham CO, Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States- based rheumatoid arthritis registry. ACR Open Rheumatol. 2021 Mar;3(3): 173-184. doi:10.1002/acr2.11232. Epub 2021 Feb 11.; Montastruc F, Renoux C, Hudson M, et al. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. Semin Arthritis Rheum. 2019 Jun;48(6):1053-1058. doi:10.1016/j.semarthrit.2019.01.009. Epub 2019 Jan 25.; Ozen G, Pedro S, Schumacher R, et al. Safety of abatacept compared with other biologic and conventional synthetic diseasemodifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. Arthritis Res Ther. 2019 Jun 7; 21(1):141. doi:10.1186/s13075-019-1921-z.; Pawar A, Desai RJ, Gautam N, Kim SC. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2020 Feb;2(2):e84-e98. doi:10.1016/S2665-9913(19)30137-7.; Patel V, Pulungan Z, Shah A, et al. Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying antirheumatic drugs. J Med Econ. 2021 Jan-Dec; 24(1):299-307. doi:10.1080/13696998.2021.1881525.; Simon TA, Boers M, Hochberg M, et al. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. Arthritis Res Ther. 2019 Nov 8;21(1):228. doi:10.1186/s13075-019-1992-x.; Cohen S, Radominski SC, Gomez-Rei no JJ, et al. Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi:10.1002/art.38779.; Smolen JS, Genovese MC, Takeuchi T, et al. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with Over 2 Years Median Time in Treatment. J Rheumatol. 2019 Jan;46(1):7-18. doi:10.3899/jrheum.171361. Epub 2018 Sep 15.; Almanzar G, Kienle F, Schmalzing M, et al. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019 Nov 1;58(11):2051-2060. doi:10.1093/rheumatology/kez175. PMID: 31106368.; Atzeni F, Talotta R, Nucera V, et al. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev Clin Immunol. 2018 Nov;14(11): 945-956. doi:10.1080/1744666X.2018.1504678. Epub 2018 Aug 21.; Буханова ДВ, Белов БС, Тарасова ГМ и др. Коморбидные инфекции при ревматических заболеваниях (по данным ФГБНУ НИИР им. В.А. Насоновой). Медицинский Совет. 2019;(9):86-91.; Баранова ММ, Муравьева НВ, Белов БС и др. Коморбидные инфекции у больных спондилоартритами: частота, структура, факторы риска. Современная ревматология. 2023;17(4):64-70. doi:10.14412/1996-7012-2023-4-64-70.
-
5Academic Journal
Authors: A. O. Bobkova, A. M. Lila, A. E. Karateev, I. A. Guseva, E. Yu. Samarkina, M. V. Shabatina, N. V. Konovalova, D. A. Varlamov, А. О. Бобкова, А. М. Лила, А. Е. Каратеев, И. А. Гусева, Е. Ю. Самаркина, М. В. Шабатина, Н. В. Коновалова, Д. А. Варламов
Source: Modern Rheumatology Journal; Том 19, № 1 (2025); 20-28 ; Современная ревматология; Том 19, № 1 (2025); 20-28 ; 2310-158X ; 1996-7012
Subject Terms: ингибиторы Янус-киназ, therapy efficacy, gene polymorphism, biologic disease-modifying antirheumatic drugs, Janus kinase inhibitors, эффективность терапии, полиморфизм генов, генно-инженерные биологические препараты
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1697/1555; https://mrj.ima-press.net/mrj/article/view/1697/1561; Насонов ЕЛ. Перспективы фармакотерапии ревматоидного артрита: новые возможности и рекомендации. Терапевтический архив. 2016; 88(12):4-10.; Thomas K, Lazani A, Kaltsonoudis E, et al. Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. Ther Adv Musculoskelet Dis. 2020 Sep 28:12:1759720X20937132. doi:10.1177/1759720X20937132. eCollection 2020.; Yu C. et al. Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol. 2019 Mar;38(3):727-738. doi:10.1007/s10067-018-4340-7. Epub 2018 Oct 19.; Бобкова АО, Лила АМ. Проблема переключений генно-инженерных биологических препаратов и ингибиторов Янус-киназ у пациентов с ревматоидным артритом. Современная ревматология. 2023; 17(3):82-88. doi; 10.14412/1996-7012-2023-3-82-88; Гордеев АВ, Олюнин ЮА, Галушко ЕА и др. Труднолечимый ревматоидный артрит. Какой он? Современная ревматология. 2021;15(5):7-11. doi:10.14412/1996-7012-2021-5-7-11; Smolen J, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 Feb 8:4:18001. doi:10.1038/nrdp.2018.1; Kerschbaumer A, Sepriano A, Bergstra SA, et al. Efficacy of synthetic and biological DMARDs: A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023 Jan;82(1):95-106. doi:10.1136/ard-2022-223365. Epub 2022 Nov 11.; Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi:10.1136/ard-2022-223356. Epub 2022 Nov 10.; Wei K, Jiang P, Zhao J, et al. Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis. Front Immunol. 2022 Mar 28;13:865267. doi:10.3389/fimmu.2022.865267.; Wei M, Chu CQ. Prediction of treatment response: Personalized medicine in the management of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2022 Mar;36(1):101741. doi:10.1016/j.berh.2021.101741. Epub 2022 Jan 19.; Yoshii I, Sawada N, Chijiwa T. Clinical characteristics and variants that predict prognosis of difficult-to-treat rheumatoid arthritis. Rheumatol Int. 2022 Nov;42(11):1947-1954. doi:10.1007/s00296-022-05124-1. Epub 2022 Apr 11.; Watanabe R, Hashimoto M, Murata K, et al. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunol Med. 2022 Mar; 45(1):35-44. doi:10.1080/25785826.2021.1928383. Epub 2021 May 25.; Novella-Navarro M, Plasencia C, Tornero C, et al. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2020 Dec 9;22(1): 284. doi:10.1186/s13075-020-02354-1; Gamboa-Cardenas RV, Ugarte-Gil MF, Loreto M, et al. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. Clin Rheumatol. 2019 Oct; 38(10):2737-2746. doi:10.1007/s10067-019-04618-x. Epub 2019 Jun 3.; Авдеева АС, Кусевич ДА. Роль лабораторных биомаркеров в прогнозировании эффективности терапии ритуксимабом при ревматоидном артрите (новые данные). Научно-практическая ревматология. 2017;55(3):295-303.; Law-Wan J, Sparfel MA, Derolez S, et al. Predictors of response to TNF inhibitors in rheumatoid arthritis: An individual patient data pooled analysis of randomised controlled trials. RMD Open. 2021 Nov;7(3):e001882. doi:10.1136/rmdopen-2021-001882.; Roodenrijs NMT, Welsing PMJ, van Roon J, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search // Rheumatology (United Kingdom). Rheumatology (Oxford). 2022 Aug 30;61(9):3552-3566. doi:10.1093/rheumatology/keac114.; Nouri B, Nair N, Barton A. Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology (Oxford). 2020 Dec 1;59(12):3603-3610. doi:10.1093/rheumatology/keaa529.; Ciccacci C, Conigliaro P, Perricone C, et al. Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis. Clin Exp Immunol. 2016 Nov;186(2): 157-163. doi:10.1111/cei.12831. Epub 2016 Aug 2.; Tarakji I, Habbal W, Monem F. Association Between STAT4 rs7574865 Polymorphism and Rheumatoid Arthritis: Debate Unresolved. Open Rheumatol J. 2018 Oct 24:12: 172-178. doi:10.2174/1874312901812010172. eCollection 2018.; Gao W, Dong X, Yang Z, et al. Association between rs7574865 polymorphism in STAT4 gene and rheumatoid arthritis: An updated meta-analysis. Eur J Intern Med. 2020 Jan;71:101-103. doi:10.1016/j.ejim.2019.11.009. Epub 2019 Nov 19.; Santillan-Lopez E, Muсoz-Valle JF, Oregon-Romero E, et al. Analysis of TNFSF13B polymorphisms and BAFF expression in rheumatoid arthritis and primary Sjögren’s syndrome patients. Mol Genet Genomic Med. 2022 Jun;10(6):e1950. doi:10.1002/mgg3.1950. Epub 2022 Apr 12.; Wang YL, Li XY , Liu L, et al. Evaluation of genetic polymorphisms in TNF 308G/A rs1800629 associated with susceptibility and severity of rheumatoid arthritis: A systematic review and meta analysis. Exp Ther Med. 2024 May 13;28(1):279. doi:10.3892/etm.2024.12567. eCollection 2024 Jul.; Toonen EJM, Barrera P, Fransen J, et al. Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis. Arthritis Res Ther. 2012 Dec 7;14(6):R264. doi:10.1186/ar4110.; Shen N, Ruan Y, Lu Y, et al. Three single nucleotide polymorphisms of TNFAIP3 gene increase the risk of rheumatoid arthritis. Oncotarget. 2017 Mar 28;8(13):20784-20793. doi:10.18632/oncotarget.15265.; Liu W, Yang Z, Chen Y, et al. The Association Between CTLA-4, CD80/86, and CD28 Gene Polymorphisms and Rheumatoid Arthritis: An Original Study and Meta-Analysis. Front Med (Lausanne). 2021 Feb 2:8:598076. doi:10.3389/fmed.2021.598076. eCollection 2021.; Zhou C, Gao S, Yuan X, et al. Association between CTLA-4 gene polymorphism and risk of rheumatoid arthritis: a meta-analysis. Aging (Albany NY). 2021 Aug 2;13(15):19397-19414. doi:10.18632/aging.203349. Epub 2021 Aug 2.; Pete NM, Del Mar Maldonado Montoro M, Perez Ramirez C, et al. Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis. J Pers Med. 2020 Nov 11;10(4):220. doi:10.3390/jpm10040220.; Sainz L, Riera P, Moya P, et al. Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis. Pharmaceutics. 2022 Sep 14;14(9): 1942. doi:10.3390/pharmaceutics14091942.; Schotte H, Schmidt H, Gaubitz M, et al. Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis. Clin Rheumatol. 2015 Dec;34(12):2021-8. doi:10.1007/s10067-015-3107-7. Epub 2015 Nov 3.; Augusto Silva dos Santos Rodrigues P, Lima de Oliveira , Mattos Brandгo K, et al. Genetic variants in the TNF pathway impact TNFi response in a mixed population with rheumatoid arthritis. Gene. 2024 Nov 30:928: 148804. doi:10.1016/j.gene.2024.148804. Epub 2024 Jul 30.; Sainz L, Riera P, Moya P, et al. Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis. Arthritis Res Ther. 2023 Nov 24; 25(1):226. doi:10.1186/s13075-023-03209-1.; Janahiraman S. et al. Genetic Biomarkers as Predictors of Response to Tocilizumab in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Genes (Basel). 2022 Jul 20;13(7):1284. doi:10.3390/genes13071284.; Schotte H, Too CL, Lee KW, et al. Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis. PLoS One. 2015 Jun 24;10(6):e0130907. doi:10.1371/journal.pone.0130907. eCollection 2015.; Robledo G, Davila-Fajardo CL, Marquez A, et al. Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases. DNA Cell Biol. 2012 Sep; 31(9):1486-91. doi:10.1089/dna.2012.1684. Epub 2012 Jun 26.; Zhang X, Li W, Zhang X, et al. Single nucleotide polymorphisms in TNFAIP3 were associated with the risks of rheumatoid arthritis in northern Chinese Han population. BMC Med Genet. 2014 May 15;15:56. doi:10.1186/1471-2350-15-56.; Wang MJ, Yang HY, Zhang H, et al. TNFAIP3 gene rs10499194, rs13207033 polymorphisms decrease the risk of rheumatoid arthritis. Oncotarget. 2016 Dec 13;7(50): 82933-82942. doi:10.18632/oncotarget.12638.; Гусева ИА, Демидова НВ, Сорока НЕ и др. Исследование полиморфизмов генов-кандидатов иммунного ответа как маркеров риска развития ревматоидного артрита и продукции аутоантител. Научно-практическая ревматология. 2016; 54(1):21-30.; Гусева ИА. Молекулярно-генетическая характеристика раннего ревматоидного артрита. Молекулярная медицина. 2016; 14(1):15-21.; Гусева ИА, Крылов МЮ, Демидова НВ и др. Полиморфизм rs7574865 гена STAT4 и риск развития раннего ревматоидного артрита (исследование Ремарка). Научно-практическая ревматология. 2019;57(1):62-65.; Elshazli R, Settin A. Association of PTPN22 rs2476601 and STAT4 rs7574865 polymorphisms with rheumatoid arthritis: A meta-analysis update. Immunobiology. Immunobiology. 2015 Aug;220(8):1012-24. doi:10.1016/j.imbio.2015.04.003. Epub 2015 Apr 28.; Ebrahimiyan H, Mostafaei S, Aslani S, et al. Studying the Association between STAT4 Gene Polymorphism and Susceptibility to Rheumatoid Arthritis Disease: An Updated Meta-Analysis. Iran J Immunol. 2019 Mar;16(1):71-83. doi:10.22034/IJI.2019.39408.; Conigliaro P, Ciccacci C, Politi C, et al. Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis. PLoS One. 2017 Jan 20;12(1):e0169956. doi:10.1371/journal.pone.0169956. eCollection 2017.; Juge PA, Gazal S, Constantin A, et al. Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open. 2017 Sep 28;3(2):e000448. doi:10.1136/rmdopen2017-000448. eCollection 2017.; Jiang X, Zhou Z, Zhang Y, et al. An updated meta-analysis of the signal transducer and activator of transcription 4 (STAT4) rs7574865 G/T polymorphism and rheumatoid arthritis risk in an Asian population Scand J Rheumatol. 2014;43(6):477-80. doi:10.3109/03009742.2014.918174. Epub 2014 Sep 2.; Al-Sofi RF, Bergmann MS, Nielsen CH, et al. The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2024 May 26; 25(11):5793. doi:10.3390/ijms25115793.; Wang Z, Kong L, Zhang H, et al. Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-toLymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of AntiTNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis. Front Pharmacol. 2022 Jan 21: 12:811719. doi:10.3389/fphar.2021.811719. eCollection 2021.; Maxwel JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet. 2008 Nov 15;17(22): 3532-8. doi:10.1093/hmg/ddn245. Epub 2008 Aug 19.; Гусева ИА, Панасюк ЕЮ, Сорока НЕ и др. Ассоциативная взаимосвязь генетических маркеров с эффективностью лечения ревматоидного артрита тоцилизумабом. Научно-практическая ревматология. 2013;51(4):377-382.; Hernandez-Breijo B, Navarro-Compan V, Plasencia-Rodriguez C, et al. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. Sci Rep. 2021 Jun 2;11(1):11632. doi:10.1038/s41598-021-91177-4.; Camarena DC, Marin-Rosales M, Cruz A, et al. Analysis of TNFSF13B polymorphisms and BAFF expression in rheumatoid arthritis and primary Sjögren’s syndrome patients. Mol Genet Genomic Med. 2022 Jun;10(6):e1950. doi:10.1002/mgg3.1950. Epub 2022 Apr 12.; Wei F, Chang Y, Wei W. The role of BAFF in the progression of rheumatoid arthritis. Cytokine. 2015 Dec;76(2):537-544. doi:10.1016/j.cyto.2015.07.014. Epub 2015 Jul 18.; Costigan M, Belfer I, Griffin RS, et al. Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain. 2010 Sep;133(9):2519-27. doi:10.1093/brain/awq195. Epub 2010 Aug 18.; Chidambaran V, Gang Y, Pilipenko V, et al. Systematic Review and Meta-Analysis of Genetic Risk of Developing Chronic Postsurgical Pain. J Pain. 2020 Jan-Feb;21(1-2):2-24. doi:10.1016/j.jpain.2019.05.008. Epub 2019 May 23.; Глемба КЕ, Гусева ИА, Каратеев АЕ и др. Влияние полиморфизмов генов KCNS1, COMT и OPRM1 на развитие послеоперационной боли у пациентов с остеоартритом, перенесших тотальное эндопротезирование коленного или тазобедренного сустава. Научно-практическая ревматология. 2021;59(5):578-583.
-
6Academic Journal
Authors: E. A. Pyadushkina, A. M. Lila, E. E. Yagnenkova, V. I. Ignatyeva, E. V. Derkach, Е. А. Пядушкина, А. М. Лила, Е. Е. Ягненкова, В. И. Игнатьева, Е. В. Деркач
Source: Modern Rheumatology Journal; Том 19, № 1 (2025); 35-43 ; Современная ревматология; Том 19, № 1 (2025); 35-43 ; 2310-158X ; 1996-7012
Subject Terms: клиникоэкономический анализ, genetically engineered biological drugs, anifrolumab, belimumab, clinical and economic analysis, генно-инженерные биологические препараты, анифролумаб, белимумаб
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1699/1557; Федеральные клинические рекомендации по диагностике и лечению системной красной волчанки. Ассоциация ревматологов России. https://rheumatolog.ru/experts/klinicheskie-rekomendacii/; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2020. 448 с.; Nasonov E, Soloviev S, Davidson JE, et al. The prevalence and incidence of Systemic Lupus Erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). Lupus. 2014 Feb; 23(2):213-9. doi:10.1177/0961203313512881. Epub 2013 Nov 19.; Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016 Oct;12(10):605-20. doi:10.1038/nrrheum.2016.137. Epub 2016 Aug 25.; Nasonov E, Soloviev S, Davidson JE, et al. Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE). Lupus Sci Med. 2015 Feb 19; 2(1):e000060. doi:10.1136/lupus-2014-000060. eCollection 2015.; Nasonov E, Soloviev S, Davidson JE, et al. Systemic lupus erythematosus and associated healthcare resource consumption in selected cities from the Russian Federation, Republic of Kazakhstan and Ukraine: the ESSENCE study. J Med Econ. 2018 Oct;21(10):1006- 1015. doi:10.1080/13696998.2018.1499518. Epub 2018 Jul 25.; Рекомендации по лечению системной красной волчанки. URL:http://rheumatolog.ru/upload/iblock/2e3/3tw49hdcelhlscvvwsom7q2f3io55c61/natrec09.pdf; Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun; 78(6):736-745. doi:10.1136/annrheumdis2019-215089. Epub 2019 Mar 29.; Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014 Jun 15; 192(12):5459-68. doi:10.4049/jimmunol.1002795.; Насонов ЕЛ, Авдеева АС, Попкова ТВ. Новые возможности фармакотерапии системной красной волчанки: перспективы применения анифролумаба (моноклональные антитела к рецепторам интерферона типа I). Научно-практическая ревматология. 2021;59(5):537-546.; Пядушкина ЕА, Игнатьева ВИ, Ягненкова ЕЕ, Деркач ЕВ. Клинико-экономический анализ терапии анифролумабом пациентов с системной красной волчанкой в Российской Федерации. Медицинские технологии. Оценка и выбор. 2023; (4):33-41.; Министерство здравоохранения Российской Федерации. Департамент регулирования обращения лекарственных средств и медицинских изделий. Трансляция заседания комиссии Министерства здравоохранения Российской Федерации по формированию перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи, 23 августа 2024 г. https://minzdrav.gov.ru/ministry/61/10/stranitsa-858/stranitsa-7801; Протокол заседания комиссии Министерства здравоохранения Российской Федерации по формированию перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи, от 23 августа 2024 г. https://minzdrav.gov.ru/ministry/61/10/stranitsa-858/stranitsa-7808; Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019 Dec;1(4):e208-e219. doi:10.1016/S2665-9913(19)30076-1. Epub 2019 Nov 11.; Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020 Jan 16; 382(3):211-221. doi:10.1056/NEJMoa1912196. Epub 2019 Dec 18.; Navarra SV, GuzmanRM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721-31. doi:10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.; Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12):3918-30. doi:10.1002/art.30613.; Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov;71(11):1833-8. doi:10.1136/annrheumdis-2011-200831. Epub 2012 May 1.; Bruce IN, Golam S, Steenkamp J, et al. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res. 2022 Jul;11(10):765-777. doi:10.2217/cer-2022-0040. Epub 2022 May 12.; Phillippo DM, Dias S, Ades AE, Welton NJ. Assessing the performance of population adjustment methods for anchored indirect comparisons: A simulation study. Stat Med. 2020 Dec 30;39(30):4885-4911. doi:10.1002/sim.8759. Epub 2020 Oct 4.; Постановление Правительства РФ от 28.08.2014 N 871 (ред. от 25.07.2024) «Об утверждении Правил формирования перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи».; Инструкция по медицинскому применению лекарственного препарата Бенлиста https://grls.rosminzdrav.ru/InstrImg/2021/09/28/1473756/79fe91aad7de-4d1a-ade4-0efc90e1e689.pdf; Инструкция по медицинскому применению лекарственного препарата Сафнело https://grls.rosminzdrav.ru/InstrImg/2023/03/17/1491908/4d650d01-6ce4-412f-9ef4-e6b1de9a34a2.pdf; Государственный реестр предельных отпускных цен производителей на лекарственные препараты, включенные в перечень жизненно необходимых и важнейших лекарственных препаратов. http://grls.rosminzdrav.ru/pricelims.aspx.; Налоговый кодекс Российской Федерации. Статья 164. Налоговые ставки. http://nalogovyykodeks.ru/statya-164.html.; Царева ОВ. Стратегическое развитие системы здравоохранения через призму реалий Программы государственных гарантий бесплатного оказания гражданам медицинской помощи. Обязательное медицинское страхование в Российской Федерации. 2024;(1):23-30.; Румянцева ЕИ, Железнякова ИА, Плахотник ОС и др. Основные изменения в модели оплаты медицинской помощи по клинико-статистическим группам в Российской Федерации в 2024 году. Медицинские технологии. Оценка и выбор. 2024; 46(2):10–21.
-
7Academic Journal
Authors: A. V. Datsina, Sh. F. Erdes, А. В. Дацина, Ш. Ф. Эрдес
Source: Modern Rheumatology Journal; Том 19, № 1 (2025); 72-75 ; Современная ревматология; Том 19, № 1 (2025); 72-75 ; 2310-158X ; 1996-7012
Subject Terms: схема наблюдения, biologic disease-modifying antirheumatic drugs, difficult-to-treat patients, follow-up regimen, генно-инженерные биологические препараты, труднолечимый пациент
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1705/1562; https://mrj.ima-press.net/mrj/article/view/1705/1575; The Lancet. A platinum age for rheumatology. Lancet. 2017 Jun 10;389(10086):2263. doi:10.1016/S0140-6736(17)31577-5.; Philippoteaux C, Delepine T, Cailliau E, et al.Characteristics of difficult-to-treat axial spondyloarthritis: Results of a real-world multicentric study. Joint Bone Spine. 2024 Mar; 91(2):105670. doi:10.1016/j.jbspin.2023.105670.; Mease PJ. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol. 2017 Jul;29(4):304-310. doi:10.1097/BOR.0000000000000388.; Baraliakos X, Kiltz U, Peters S, et al. Efficiency of treatment with non-steroidal antiinflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2017 Jan; 56(1):95- 102. doi:10.1093/rheumatology/kew367.; Winthrop KL, Mease P, Kerschbaumer A, et al. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Ann Rheum Dis. 2024 Mar 12;83(4):409-416. doi:10.1136/ard-2023-224916.; Эрдес ШФ, Сахарова КВ, Дубинина ТВ, Черкасова МВ. Клинические особенности больных анкилозирующим спондилитом с неэффективностью двух и более генноинженерных биологических препаратов. Современная ревматология. 2023;17(3):30-36. doi:10.14412/1996-7012-2023-3-30-36.; Danve A. Deodhar. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022 Apr;18(4):205-216. doi:10.1038/s41584-022-00761-z.; Lindström U, Olofsson T, Wedren S, et al. Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Res Ther. 2019 May 28; 21(1):128. doi:10.1186/s13075-019-1908-9.; Navarro-Compan V, Sepriano A, El-Zorkany B, et al. Axial spondyloarthritis. Ann Rheum Dis. 2021 Dec;80(12):1511-1521. doi:10.1136/annrheumdis-2021-221035.; Roodenrijs NMT, Welsing PMJ, van der Goes MC, et al. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. Rheumatology (Oxford). 2021 Oct 2;60(10): 4681-4690. doi:10.1093/rheumatology/keab078.; Molto A, Lopez-Medina C, van den Bosch FE, et al. Efficacy of a tightcontrol and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis. 2021 Nov;80(11):1436- 1444. doi:10.1136/annrheumdis-2020-219585.; Parigi TL, D'Amico F, Abreu MT, et al. Difficulttotreat inflammatory bowel disease: results from a global IOIBD survey. Lancet Gastroenterol Hepatol. 2022 May;7(5):390- 391. doi:10.1016/S2468-1253(22)00085-1.; Nagy G, Roodenrijs NMT, Welsing PMJ , et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022 Jan;81(1):20- 33. doi:10.1136/annrheumdis-2021-220973.; Lubrano E, Scriffignano S, Perrotta FM. Difficult to treat and refractory to treatment in psoriatic arthritis. Rheumatol Ther. 2023 Oct;10(5):1119-1125. doi:10.1007/s40744-023-00574-w.; Wendling D, Verhoeven F, Prati C, et al. Is the difficult-to-treat (D2T) concept applicable to axial spondyloarthritis? Joint Bone Spine. 2023 Mar;9(1):e002842. doi:10.1136/rmdopen-2022-002842.; Giuseppe D Di, Lindström U, Aaltonen K, et al. The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology (Oxford). 2022 Aug 30;61(9): 3647-3656. doi:10.1093/rheumatology/keab946.; Fakih O, Desmarets M, Martin B, et al. Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study. RMD Open. 2023 Nov 23;9(4):e003461. doi:10.1136/rmdopen2023-003461.; Dua D, Blake T. Difficult to treat spondyloarthritis: patients with a high biologic switch rate and the factors influencing it; a real world as clinic experience. https://acrabstracts.org/abstract/difficult-to-treat-spondyloarthritispatients-with-a-high-biologic-switch-rateand-the-factors-influencing-it-a-real-worldas-clinic-experience/; ASAS definition of difficult-to-treat axial spondyloarthritis. https://www.asas-group.org/asas-definition-of-difficult-to-treataxial-spondyloarthritis/; Maneiro JR, Souto A, Salgado E, et al. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and metaanalysis. RMD Open. 2015 Feb 18;1(1): e000017. doi:10.1136/rmdopen-2014-000017.; Zhao SS, Jones GT, Macfarlane GJ, et al. Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. Rheumatology (Oxford). 2021 Sep 1;60(9):4158-4165. doi:10.1093/rheumatology/keaa900.; Krabbe S, Glintborg B, Ostergaard M, et al. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis. Scand J Rheumatol. 2019 Mar;48(2):128-132. doi:10.1080/03009742.2018.1481225. Epub 2018 Aug 13.; Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010 Nov;69(11): 2002-8. doi:10.1136/ard.2009.124446. Epub 2010 May 28.; Van Der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun; 76(6):978-991. doi:10.1136/annrheumdis2016-210770.; Kearsley-Fleet L, Davies R, De Cock D, et al. BSRBR-RA Contributors Group. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018 Oct;77(10):1405-1412. doi:10.1136/annrheumdis-2018-213378. Epub 2018 Jul 6.; Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep. 2018 May 12;20(6):35. doi:10.1007/s11926-018-0744-2.; Biallas RL, Dean LE, Davidson L, et al. The role of metrology in axSpA: does it provide unique information in assessing patients and predicting outcome? Results from the BSRBR-AS registry. Arthritis Care Res (Hoboken). 2022 Apr;74(4):665-674. doi:10.1002/acr.24500.
-
8Academic Journal
Authors: O. V. Dobrovolskaya, M. V. Kozyreva, N. V. Demin, A. Yu. Feklistov, N. V. Toroptsova, О. В. Добровольская, М. В. Козырева, Н. В. Демин, А. Ю. Феклистов, Н. В. Торопцова
Source: Modern Rheumatology Journal; Том 19, № 1 (2025); 29-34 ; Современная ревматология; Том 19, № 1 (2025); 29-34 ; 2310-158X ; 1996-7012
Subject Terms: физическая работоспособность, body composition, biologic disease-modifying antirheumatic drugs, physical performance, состав тела, генно-инженерные биологические препараты
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1698/1556; Никитинская ОА, Торопцова НВ, Демин НВ и др. Риск остеопоротических переломов у больных ревматоидным артритом: результаты программы «Остеоскрининг Россия». Научно-практическая ревматология. 2018;56(3):310-315.; Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford). 2004 Oct;43(10):1219-23. doi:10.1093/rheumatology/keh321. Epub 2004 Aug 3.; Lozada-Mellado M, Llorente L, HinojosaAzaola A, et al. Inflammatory profile in patients with rheumatoid arthritis and sarcopenia. Clin Rheumatol. 2024 Jun;43(6):1865- 1870. doi:10.1007/s10067-024-06974-9. Epub 2024 Apr 26.; Dietzel R, Wiegmann S, Borucki D, et al. Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition. RMD Open. 2022 Sep;8(2):e002600. doi:10.1136/rmdopen-2022-002600.; Ngeuleu A, Allali F, Medrare L, et al. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. Rheumatol Int. 2017 Jun;37(6): 1015-1020. doi:10.1007/s00296-017-3665-x. Epub 2017 Mar 3.; Hasegawa E, Ito S, Kurosawa Y, et al. The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis. Intern Med. 2023;62(3):373-379. doi:10.2169/internalmedicine.9600-22. Epub 2023 Feb 1.; Vial G, Lambert C, Pereira B, et al. The Effect of TNF and Non-TNF-Targeted Biologics on Body Composition in Rheumatoid Arthritis. J Clin Med. 2021 Jan 29;10(3):487. doi:10.3390/jcm10030487.; Serelis J, Kontogianni MD, Katsiougiannis S, et al. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol. 2008 Jun;27(6):795-7. doi:10.1007/s10067-008-0855-7. Epub 2008 Feb 28.; Torii M, Hashimoto M, Hanai A, et al. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2019 Jul;29(4):589-595. doi:10.1080/14397595.2018.1510565. Epub 2018 Sep 11.; Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1; 48(1):16-31. doi:10.1093/ageing/afy169.; Letarouilly JG, Flipo RM, Cortet B, et al. Body composition in patients with rheumatoid arthritis: a narrative literature review. Ther Adv Musculoskelet Dis. 2021 Jun 21:13:1759 720X211015006. doi:10.1177/1759720X211015006. eCollection 2021.; Sciorati C, Gamberale R, Monno A, et al. Pharmacological blockade of TNFα prevents sarcopenia and prolongs survival in aging mice. Aging (Albany NY). 2020 Nov 26;12(23): 23497-23508. doi:10.18632/aging.202200. Epub 2020 Nov 26.; Yun HW, Kim CJ, Kim JW, et al. The Assessment of Muscle Mass and Function in Patients with Long-Standing Rheumatoid Arthritis. J Clin Med. 2021 Aug 4;10(16):3458. doi:10.3390/jcm10163458.
-
9
-
10Academic Journal
Source: Rheumatology Science and Practice; Vol 62, No 1 (2024); 109-117 ; Научно-практическая ревматология; Vol 62, No 1 (2024); 109-117 ; 1995-4492 ; 1995-4484
Subject Terms: генно-инженерные биологические препараты, juvenile idiopathic arthritis, juvenile-onset systemic lupus erythematosus, juvenile primary fibromyalgia, anxiety, depression, psychotherapy, psychopharmacotherapy, biological disease-modifying antirheumatic drugs, ювенильный идиопатический артрит, системная красная волчанка с ювенильным дебютом, ювенильная первичная фибромиалгия, тревога, депрессия, психотерапия, психофармакотерапия
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3520/2355; Kostev K, Teichgräber F, Konrad M, Jacob L. Association between chronic somatic conditions and depression in children and adolescents: A retrospective study of 13,326 patients. J Affect Disord. 2019;245:697-701. doi:10.1016/j.jad.2018.11.014; Williams NA, Burnfield JM. Psychological difficulties and parental well-being in children with musculoskeletal problems in the 2011/2012 National Survey of Children’s Health. Rehabil Psychol. 2019;64(1):87-97. doi:10.1037/rep0000251; Miller AH, Raison CL. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. doi:10.1038/nri.2015.5; Suneson K, Lindahl J, Chamli Hårsmar S, Söderberg G, Lindqvist D. Inflammatory depression-mechanisms and non-pharmacological interventions. Int J Mol Sci. 2021;22(4):1640. doi:10.3390/ijms22041640; Davis AM, Rubinstein TB, Rodriguez M, Knight AM. Mental health care for youth with rheumatologic diseases – bridging the gap. Pediatr Rheumatol Online J. 2017;15(1):85. doi:10.1186/s12969-017-0214-9; Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. doi:10.1016/S0140-6736(07)60363-8; Korte-Bouws GAH, Albers E, Voskamp M, Hendriksen H, de Leeuw LR, Güntürkün O, et al. Juvenile arthritis patients suffering from chronic inflammation have increased activity of both IDO and GTP-CH1 pathways but decreased BH4 efficacy: Implications for well-being, including fatigue, cognitive impairment, anxiety, and depression. Pharmaceuticals (Basel). 2019;12(1):9. doi:10.3390/ph12010009; Reda MM, Hosny E, AbuSenna H. Psychiatric morbidity in patients with rheumatoid juvenile arthritis: A SPECT study. Middle East Curr Psychiat. 2011;18(3):132-137. doi:10.1097/01.XME.0000398422.59986.78; Hanns L, Cordingley L, Galloway J, Norton S, Carvalho LA, Christie D, et al. Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford). 2018;57(8):1381-1389. doi:10.1093/rheumatology/key088; El-Najjar AR, Negm MG, El-Sayed WM. The relationship between depression, disease activity and physical function in juvenile idiopathic arthritis patients in Zagazig University Hospitals – Egypt. Egypt Rheumatologist. 2014;36(3):145-150. doi:10.1016/j.ejr.2014.01.001; Tarakci E, Yeldan I, Kaya Mutlu E, Baydogan SN, Kasapcopur O. The relationship between physical activity level, anxiety, depression, and functional ability in children and adolescents with juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(11):1415-1420. doi:10.1007/s10067-011-1832-0; Fair DC, Rodriguez M, Knight AM, Rubinstein TB. Depression and anxiety in patients with juvenile idiopathic arthritis: Current insights and impact on quality of life, a systematic review. Open Access Rheumatol. 2019;11:237-252. doi:10.2147/OARRR. S174408; Сантимов АВ, Часнык ВГ, Гречаный СВ. Психометрическая оценка хронического болевого синдрома при ювенильном идиопатическом артрите. Педиатр. 2019;10(3):25-30. [Santimov AV, Chasnyk VG, Grechanyi SV. Psychometric assessment of chronic pain syndrome in juvenile idiopathic arthritis. Pediatrician (St. Petersburg). 2019;10(3):25-30 (In Russ.)]. doi:10.17816/PED10325-30; Сантимов АВ, Часнык ВГ, Гречаный СВ. Уровень тревоги и депрессии у детей и подростков с хроническим болевым синдромом (на примере ювенильного идиопатического артрита). Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2019;4-2:78-86. doi:10.31363/2313-7053-2019-4-2-78-86; Зубарева ЕС, Генералова ДД, Сантимов АВ, Новик ГА, Тамразова ОБ, Гречаный СВ. Выявление нарушений психического здоровья при ювенильном идиопатическом артрите с хроническим болевым синдромом. Педиатрия им. Г.Н. Сперанского. 2023;102(4):147-158. doi:10.24110/0031-403X-2023-102-4-147-158; Kyllönen MS, Ebeling H, Kautiainen H, Puolakka K, Vähäsalo P. Psychiatric disorders in incident patients with juvenile idiopathic arthritis – a case-control cohort study. Pediatr Rheumatol Online J. 2021;19(1):105. doi:10.1186/s12969-021-00599-x; Berthold E, Dahlberg A, Jöud A, Tydén H, Månsson B, Kahn F, et al. The risk of depression and anxiety is not increased in individuals with juvenile idiopathic arthritis – results from the SouthSwedish Juvenile Idiopathic Arthritis Cohort. Pediatr Rheumatol Online J. 2022;20(1):114. doi:10.1186/s12969-022-00765-9; Delcoigne B, Horne A, Reutfors J, Askling J. Risk of psychiatric disorders in juvenile idiopathic arthritis: Population- and siblingcontrolled cohort and cross-sectional analyses. ACR Open Rheumatol. 2023;5(5):277-284. doi:10.1002/acr2.11549; Mann CM, Schanberg LE, Wang M, von Scheven E, Lucas N, Hernandez A, et al. Identifying clinically meaningful severity categories for PROMIS pediatric measures of anxiety, mobility, fatigue, and depressive symptoms in juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus. Qual Life Res. 2020;29(9):2573-2584. doi:10.1007/s11136-020-02513-6; Kısaarslan AP, Çiçek SÖ, Batu ED, Şahin S, Gürgöze MK, Çetinkaya SB, et al. Neuropsychiatric involvement in juvenileonset systemic lupus erythematosus: A multicenter study. Joint Bone Spine. 2023;90(4):105559. doi:10.1016/j.jbspin.2023.105559; Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023;10(1):5. doi:10.1186/s40348-023-00161-7; Donnelly C, Cunningham N, Jones JT, Ji L, Brunner HI, Kashikar-Zuck S. Fatigue and depression predict reduced health-related quality of life in childhood-onset lupus. Lupus. 2018;27(1):124- 133. doi:10.1177/0961203317716317; Каледа МИ, Никишина ИП. Нейропсихические нарушения при системной красной волчанке с ювенильным дебютом. Научно-практическая ревматология. 2020;58(4):437-442. doi:10.47360/1995-4484-2020-437-442; Каледа МИ, Никишина ИП, Глухова СИ, Степаненко НЮ.Нейропсихические нарушения при ювенильном дебюте системной красной волчанки: результаты ретроспективного исследования. Научно-практическая ревматология. 2020;58(2):171-177. doi:10.14412/1995-4484-2020-171-177; Кучинская ЕМ, Яковлева ЮА, Ракова МА, Любимова НА, Суспицын ЕН, Костик ММ. Системная красная волчанка с нейропсихическими проявлениями у ребенка: описание клинического случая и обзор международных рекомендаций по диагностике и лечению. Российский вестник перинатологии и педиатрии. 2021;66(1):98-105. doi:10.21508/1027-4065-2021-66-1-98-105; Кучинская ЕМ, Часнык ВГ, Костик ММ. Системная красная волчанка у детей: применение формализованных методов описания течения и исхода заболевания в ретроспективном исследовании. Педиатр. 2017;8(5):35-43. doi:10.17816/PED8535-43; Giani T, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al.; UK JSLE Cohort Study. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus. 2021;30(12):1955-1965. doi:10.1177/09612033211045050; Knight AM, Xie M, Mandell DS. Disparities in psychiatric diagnosis and treatment for youth with systemic lupus erythematosus: Analysis of a national US Medicaid sample. J Rheumatol. 2016;43(7):1427-1433. doi:10.3899/jrheum.150967; Coles ML, Weissmann R, Uziel Y. Juvenile primary fibromyalgia syndrome: Epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis. Pediatr Rheumatol Online J. 2021;19(1):22. doi:10.1186/s12969-021-00493-6; Kashikar-Zuck S, Parkins IS, Graham TB, Lynch AM, Passo M, Johnston M, et al. Anxiety, mood, and behavioral disorders among pediatric patients with juvenile fibromyalgia syndrome. Clin J Pain. 2008;24(7):620-626. doi:10.1097/AJP.0b013e31816d7d23; Conte PM, Walco GA, Kimura Y. Temperament and stress response in children with juvenile primary fibromyalgia syndrome. Arthritis Rheum. 2003;48(10):2923-2930. doi:10.1002/art.11244; Kashikar-Zuck S, Cunningham N, Peugh J, Black WR, Nelson S, Lynch-Jordan AM, et al. Long-term outcomes of adolescents with juvenile-onset fibromyalgia into adulthood and impact of depressive symptoms on functioning over time. Pain. 2019;160(2):433-441. doi:10.1097/j.pain.0000000000001415; Connelly M, Weiss JE. Pain, functional disability, and their association in juvenile fibromyalgia compared to other pediatric rheumatic diseases. Pediatr Rheumatol. 2019;17(1):72. doi:10.1186/s12969-019-0375-9; Weiss JE, Schikler KN, Boneparth AD, Connelly M. Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Pediatr Rheumatol. 2019;17(1):1-8. doi:10.1186/s12969-019-0356-z; Siegel DM, Janeway D, Baum J. Fibromyalgia syndrome in children and adolescents: Clinical features at presentation and status at follow-up. Pediatrics. 1998;101(3 Pt 1):377-382. doi:10.1542/peds.101.3.377; Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221-227. doi:10.1001/archinte.160.2.221; Gmuca S, Sherry DD. Fibromyalgia: Treating pain in the juvenile patient. Pediatr Drugs. 2017;19(4):325-338. doi:10.1007/s40272-017-0233-5; Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol. 2006;2(8):416-424. doi:10.1038/ncprheum0245; Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham TB, et al. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: A multisite, single-blind, randomized, controlled clinical trial. Arthritis Rheum. 2012;64(1):297-305. doi:10.1002/art.30644; Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2018;9(9):CD003968. doi:10.1002/14651858.CD003968.pub5; Сантимов АВ, Часнык ВГ, Гречаный СВ. Психотерапевтический подход к лечению хронического болевого синдрома при ювенильном идиопатическом артрите и предикторы его эффективности. Психиатрия, психотерапия и клиническая психология. 2022;13(2):138-150. doi:10.34883/PI.2022.13.2.010; Trachtman R, Samuels J, Wojtal E, Feldman BM. Resilience and its associations in children with systemic lupus erythematosus and juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2023;21(1):67. doi:10.1186/s12969-023-00854-3; Ross E, Abulaban K, Kessler E, Cunningham N. Non-pharmacologic therapies in treatment of childhood-onset systemic lupus erythematosus: A systematic review. Lupus. 2022;31(7):864-879. doi:10.1177/09612033221094704; Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16(9):1347-1368. doi:10.1517/14656566.2015.1047343; Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2(2):CD010292. doi:10.1002/14651858.CD010292.pub2; Upadhyaya HP, Arnold LM, Alaka K, Qiao M, Williams D, Mehta R. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatr Rheumatol Online J. 2019;17(1):27. doi:10.1186/s12969-019-0325-6; Arnold LM, Bateman L, Palmer RH, Lin Y. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: Lessons from a clinical trial program. Pediatr Rheumatol Online J. 2015;13:27. doi:10.1186/s12969-015-0025-9; Mariutto EN, Stanford SB, Kashikar-Zuck S, Welge JA, Arnold LM. An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia. J Clin Psychopharmacol. 2012;32(2):293-295. doi:10.1097/JCP.0b013e31824858dc; Nishishinya B, Urrútia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, et al. Amitriptyline in the treatment of fibromyalgia: A systematic review of its efficacy. Rheumatology (Oxford). 2008;47(12):1741-1746. doi:10.1093/rheumatology/ken317; Migliorini F, Maffulli N, Knobe M, Tenze G, Aljalloud A, Colarossi G. Pregabalin administration in patients with fibromyalgia: A Bayesian network meta-analysis. Sci Rep. 2022;12(1):12148. doi:10.1038/s41598-022-16146-x; Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336-1344. doi:10.1002/art.22457; Egunsola O, Wylie CE, Chitty KM, Buckley NA. Systematic review of the efficacy and safety of gabapentin and pregabalin for pain in children and adolescents. Anesth Analg. 2019;128(4):811-819. doi:10.1213/ANE.0000000000003936; Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, BhadraBrown P, et al.; Pregabalin Adolescent Fibromyalgia Study Group. Safety and efficacy of pregabalin in adolescents with fibromyalgia: A randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016;14(1):46. doi:10.1186/s12969-016-0106-4; Ting EY, Yang AC, Tsai SJ. Role of interleukin-6 in depressive disorder. Int J Mol Sci. 2020;21(6):2194. doi:10.3390/ijms21062194; Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин 6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318-327. doi:10.14412/1995-4484-2019-318-327; Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: Towards precision medicine. Nat Rev Drug Discov. 2022;21(3):224-244. doi:10.1038/s41573-021-00368-1; Лисицына ТА, Абрамкин АА, Вельтищев ДЮ, Серавина ОФ, Ковалевская ОБ, Борисова АБ, и др. Эффективность олокизумаба в отношении коморбидного депрессивного расстройства у больных ревматоидным артритом: предварительные результаты исследования. Научно-практическая ревматология. 2023; 61(2):188-198. doi:10.47360/1995-4484-2023-188-198; Coskun Benlidayi I. Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol Int. 2019;39(5):781-791. doi:10.1007/s00296-019-04251-6; Mendieta D, De la Cruz-Aguilera DL, Barrera-Villalpando MI, Becerril-Villanueva E, Arreola R, Hernández-Ferreira E, et al. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol. 2016;290:22-25. doi:10.1016/j.jneuroim.2015.11.011; Ranzolin A, Duarte AL, Bredemeier M, da Costa Neto CA, Ascoli BM, Wollenhaupt-Aguiar B, et al. Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia – A controlled cross-sectional study. Cytokine. 2016;84:25-28. doi:10.1016/j.cyto.2016.05.011; Pernambuco AP, Schetino LP, Alvim CC, Murad CM, Viana RS, Carvalho LS, et al. Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol. 2013;31(6 Suppl 79):S60-S63.; Mastrangelo F, Frydas I, Ronconi G, Kritas SK, Tettamanti L, Caraffa Al, et al. Low-grade chronic inflammation mediated by mast cells in fibromyalgia: Role of IL-37. J Biol Regul Homeost Agents. 2018;32(2):195-198.; Loncharich MF, Robertson I. Anifrolumab in systemic lupus erythematosus. Drugs Today (Barc). 2023;59(2):53-61. doi:10.1358/dot.2023.59.2.3521876; Алексеева ЕИ, Денисова РВ, Валиева СИ, Бзарова ТМ, Слепцова ТВ, Чомахидзе АМ, и др. Эффективность и безопасность ритуксимаба у детей с системной красной волчанкой: результаты ретроспективного исследования серии случаев. Вопросы современной педиатрии. 2016;15(5):497-504. doi:10.15690/vsp.v15i5.1624; Калашникова ЭМ, Раупов РК, Любимова НА, Кучинская ЕМ, Масалова ВВ, Исупова ЕА, и др. Опыт применения ритуксимаба у пациентов с ювенильной системной красной волчанкой: предварительные результаты двуцентрового когортного исследования. Российский вестник перинатологии и педиатрии. 2023;68(1):74-84. doi:10.21508/1027-4065-2023-68-1-74-84; Santimov A, Grom AA. Other biological therapies for pediatric rheumatic diseases. Handbook Syst Autoimmun Dis. 2016;11:503-525. doi:10.1016/B978-0-444-63596-9.00024-4; Plüß M, Tampe B, Niebusch N, Zeisberg M, Müller GA, Korsten P. Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus. Front Med (Lausanne). 2020;7:222. doi:10.3389/fmed.2020.00222; Cheng H, Zhang XY, Yang HD, Yu Z, Yan CL, Gao C, et al. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol. 2022;13:911730. doi:10.3389/fimmu.2022.911730; Bangert E, Wakani L, Merchant M, Strand V, Touma Z. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: Review of clinical studies. Patient Relat Outcome Meas. 2019;10:1-7. doi:10.2147/PROM.S134326; Xu Y, Xu JW, Wang YJ, Tung TH, Chien CW. Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: A systematic review and metaanalysis of randomised controlled trials. Int Immunopharmacol. 2022;109:108811. doi:10.1016/j.intimp.2022.108811
-
11Academic Journal
Authors: Yu. N. Gorbunova, L. V. Kondratyeva, T. V. Popkova, N. V. Demin, A. V. Smirnov, E. L. Nasonov, Ю. Н. Горбунова, Л. В. Кондратьева, Т. В. Попкова, Н. В. Дёмин, А. В. Смирнов, Е. Л. Насонов
Contributors: Статья подготовлена в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» (№ государственного задания PK 123041800015-7).
Source: Rheumatology Science and Practice; Vol 62, No 5 (2024); 523-528 ; Научно-практическая ревматология; Vol 62, No 5 (2024); 523-528 ; 1995-4492 ; 1995-4484
Subject Terms: ингибиторы фактора некроза опухоли альфа, obesity, body composition, lean and fat mass, dual-energy X-ray absorptiometry, methotrexate, biological therapy, biologic Disease modifying anti-rheumatic disease, tumour necrosis factor alpha inhibitors, ожирение, состав тела, тощая и жировая масса, двухэнергетическая рентгеновская абсорбциометрия, метотрексат, генно-инженерные биологические препараты
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3638/2406; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. doi:10.1016/S0140-6736(16)30173-8; Yoshida T, Hashimoto M, Kawahara R, Yamamoto H, Tanaka M, Ito H, et al. Non-obese visceral adiposity is associated with the risk of atherosclerosis in Japanese patients with rheumatoid arthritis: A cross-sectional study. Rheumatol Int. 2018;38(9):1679-1689. doi:10.1007/s00296-018-4095-0; Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al.; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601. doi:10.1093/ageing/afz046; Cui C, Mackey RH, Shaaban CE, Kuller LH, Lopez OL, Sekikawa A. Associations of body composition with incident dementia in older adults: Cardiovascular Health Study-Cognition Study. Alzheimers Dement. 2020;16(10):1402-1411. doi:10.1002/alz.12125; Tournadre A, Vial G, Capel F, Soubrier M, Boirie Y. Sarcopenia. Joint Bone Spine. 2019;86(3):309-314. doi:10.1016/j.jbspin.2018.08.001; Radkowski MJ, Sławiński P, Targowski T. Osteosarcopenia in rheumatoid arthritis treated with glucocorticosteroids – Essence, significance, consequences. Reumatologia. 2020;58:101-106. doi:10.5114/reum.2020.95363; Stanley A, Schuna J, Yang S, Kennedy S, Heo M, Wong M, et al. Distinct phenotypic characteristics of normal-weight adults at risk of developing cardiovascular and metabolic diseases. Am J Clin Nutr. 2020;112(4):967-978. doi:10.1093/ajcn/nqaa194; Shetty S, Kapoor N, Thomas N, Paul TV. DXA measured visceral adipose tissue, total fat, anthropometric indices and its association with cardiometabolic risk factors in mother-daughter pairs from India. J Clin Densitom. 2021;24(1):146-155. doi:10.1016/j.jocd.2020.06.001; Chen Y, He D, Yang T, Zhou H, Xiang S, Shen L, et al. Relationship between body composition indicators and risk of type 2 diabetes mellitus in Chinese adults. BMC Public Health. 2020;20(1):452. doi:10.1186/s12889-020-08552-5; England BR, Baker JF, Sayles H, Michaud K, Caplan L, Davis LA, et al. Body mass index, weight loss, and cause-specific mortality in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018;70(1):11-18. doi:10.1002/acr.23258; George M, Baker JF. The obesity epidemic and consequences for rheumatoid arthritis care. Curr Rheumatol Rep. 2016;18:6. doi:10.1007/s11926-015-0550-z; Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-271.; Letarouilly JG, Flipo RM, Cortet B, Tournadre A, Paccou J. Body composition in patients with rheumatoid arthritis: A narrative literature review. Ther Adv Musculoskelet Dis. 2021;13:1-21. doi:10.1177/1759720X211015006; Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006;84(6):1463-1472. doi:10.1093/ajcn/84.6.1463; Engvall IL, Tengstrand B, Brismar K, Hafström I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: A randomised study over 21 months. Arthritis Res Ther. 2010;12(5):R197. doi:10.1186/ar3169; Sellen DW. Physical status: The use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organization Technical Report Series. 1995;854(1):452. doi:10.1017/S0021932098261359; Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M, et al. Abnormal body composition phenotypes in older rheumatoid arthritis patients: Association with disease characteristics and pharmacotherapies. Arthritis Rheum. 2008;59(6):807-815. doi:10.1002/art.23719; Добровольская ОВ, Торопцова НВ, Феклистов АЮ, Демин НВ, Сорокина АО, Никитинская ОА. Фенотипы состава тела, физическая работоспособность и качество жизни у женщин с ревматоидным артритом. Терапевтический архив. 2022;94(5):654-660.; Toussirot É, Mourot L, Dehecq B, Wendling D, Grandclément É, Dumoulin G; CBT-506. TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: A 2-year prospective study. Eur J Nutr. 2014;53(3):951-961. doi:10.1007/s00394-013-0599-2; Serelis J, Kontogianni MD, Katsiougiannis S, Bletsa M, Tektonidou MG, Skopouli FN. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol. 2008;27(6):795-797. doi:10.1007/s10067-008-0855-7; Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, Koutedakis Y, Nevill AM, Panoulas VF, et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: Effects on components of rheumatoid cachexia. Rheumatology (Oxford). 2007;46(12):1824-1827. doi:10.1093/rheumatology/kem291; Dao HH, Do QT, Sakamoto J. Abnormal body composition phenotypes in Vietnamese women with early rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1250-1258. doi:10.1093/rheumatology/ker004; Dessein PH, Solomon A, Hollan I. Metabolic abnormalities in patients with inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2016;30:901-915. doi:10.1016/j.berh.2016.10.001; Vial G, Lambert C, Pereira B, Couderc M, Malochet-Guinamand S, Mathieu S, et al. The effect of TNF and non-TNF-targeted biologics on body composition in rheumatoid arthritis. J Clin Med. 2021;10(3):487. doi:10.3390/jcm10030487; Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8(4):639-646. doi:10.1002/jcsm.12189; Toussirot E, Marotte H, Mulleman D, Cormier G, Coury F, Gaudin P, et al. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: A 12-month multicentre study. Arthritis Res Ther. 2020;22(1):224. doi:10.1186/s13075-020-02297-7; Chikugo M, Sebe M, Tsutsumi R, Iuchi M, Kishi J, Kuroda M, et al. Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism. J Med Invest. 2018;65(3.4):166-170. doi:10.2152/jmi.65.166; Lemmey AB, Wilkinson TJ, Clayton RJ, Sheikh F, Whale J, Jones HS, et al. Tight control of disease activity fails to improve body composition or physical function in rheumatoid arthritis patients. Rheumatology (Oxford). 2016;55(10):1736-1745. doi:10.1093/rheumatology/kew243; Levitsky A, Brismar K, Hafström I, Hambardzumyan K, Lourdudoss C, van Vollenhoven RF, et al. Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: Results from the SWEFOT trial. RMD Open. 2017;3(2):e000458. doi:10.1136/rmdopen-2017-000458; Juan S, Jiabi Z. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis. Joint Bone Spine. 2019;86(2):173-183. doi:10.1016/j.jbspin.2018.03.007
-
12Academic Journal
Authors: N. V. Trushenko, B. B. Lavginova, V. A. Stener, S. N. Avdeev, Н. В. Трушенко, Б. Б. Лавгинова, В. А. Стенер, С. Н. Авдеев
Source: Meditsinskiy sovet = Medical Council; № 9 (2024); 9-16 ; Медицинский Совет; № 9 (2024); 9-16 ; 2658-5790 ; 2079-701X
Subject Terms: Т2-фенотип, remission, genetically engineered biological drugs, omalizumab, T2 phenotype, ремиссия, генно-инженерные биологические препараты, омализумаб
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8323/7343; Авдеев СН, Ненашева НМ, Жуденков КВ, Петраковская ВА, Изюмова ГВ. Распространенность, заболеваемость, фенотипы и другие характеристики тяжелой бронхиальной астмы в Российской Федерации. Пульмонология. 2018;28(3):341–358. https://doi.org/10.18093/0869-0189-2018-28-3-341-358.; Canonica GW, Blasi F, Carpagnano GE, Guida G, Heffler E, Paggiaro P et al. Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus. J Allergy Clin Immunol Pract. 2023;11(12):3629–3637. https://doi.org/10.1016/j.jaip.2023.07.041.; Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. https://doi.org/10.1016/j.jaci.2019.12.006.; Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. https://doi.org/10.1034/j.1399-3003.1999.14d29.x.; Upham JW, James AL. Remission of asthma: The next therapeutic frontier? Pharmacol Ther. 2011;130(1):38–45. https://doi.org/10.1016/j.pharmthera.2011.01.002.; Oishi K, Hamada K, Murata Y, Matsuda K, Ohata S, Yamaji Y et al. A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma. J Clin Med. 2023;12(8):2900. https://doi.org/10.3390/jcm12082900.; McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ et al. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023;62(6):2300819. https://doi.org/10.1183/13993003.00819-2023.; Bahmer T. Daily, Once-Weekly, or No Asthma Controller Therapy At All: The Annoying Issue with Disease Remission in Clinical Asthma Trials. Am J Respir Crit Care Med. 2021;203(3):273–275. https://doi.org/10.1164/rccm.202008-3161ED.; Deschildre A, Roussel J, Drumez E, Abou-Taam R, Rames C, Le Roux P et al. Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study. Allergy. 2019;74(5):999–1003. https://doi.org/10.1111/all.13678.; Rial MJ, Domínguez-Ortega J. Inflammatory Remission in T2 Severe Asthma. Front Allergy. 2022;3:923083. https://doi.org/10.3389/falgy.2022.923083.; Carpaij OA, Burgess JK, Kerstjens HAM, Nawijn MC, van den Berge M. A review on the pathophysiology of asthma remission. Pharmacol Ther. 2019;201:8–24. https://doi.org/10.1016/j.pharmthera.2019.05.002.; Sposato B, Bianchi F, Ricci A, Scalese M. Clinical Asthma Remission Obtained with Biologics in Real Life: Patients’ Prevalence and Characteristics. J Pers Med. 2023;13(6):1020. https://doi.org/10.3390/jpm13061020.; Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;2014(1):CD003559. https://doi.org/10.1002/14651858.CD003559.pub4.; Чучалин АГ, Геппе НА, Колосова НГ, Кондюрина ЕГ, Малахов АБ, Мизерницкий ЮЛ, Ревякина ВА. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 5-е изд. М.: Оригинал-макет; 2017. 160 с. Режим доступа: https://pulmodeti.ru/wp-content/uploads/BA_u_detei.pdf.; Ненашева НМ, Курбачева ОМ, Авдеев СН, Федосенко СВ, Емельянов АВ, Белевский АС и др. Практические рекомендации по выбору иммунобиологического препарата для лечения тяжелой бронхиальной астмы Т2-эндотипа. Пульмонология. 2020;30(2):227–244. https://doi.org/10.18093/0869-0189-2020-30-2-227-244.; Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.e2. https://doi.org/10.1016/j.jaip.2017.02.002.; Faulkner KM, MacDonald K, Abraham I, Alhossan A, Lee CS. “Real-world” effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Rev Clin Immunol. 2021;17(1):73–83. https://doi.org/10.1080/1744666X.2020.1856658.; Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosén K, Chipps BE et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–169.e2. https://doi.org/10.1016/j.jaci.2016.08.054.; Vennera MDC, Sabadell C, Picado C. Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma. Thorax. 2018;73(8):782–784. https://doi.org/10.1136/thoraxjnl-2017-210017.; Игнатова ГЛ, Ненашева НМ, Антонов ВН. Возможности снижения дозы генно-инженерных препаратов при тяжелой аллергической бронхиальной астме: теория и практика. Практическая аллергология. 2023;(2):26–32. Режим доступа: https://drive.google.com/file/d/1d22yXh7WTjYjdd80Tj1NqlW3XDUzLkr-/view.; Menzella F, Galeone C, Formisano D, Castagnetti C, Ruggiero P, Simonazzi A, Zucchi L. Real-life Efficacy of Omalizumab After 9 Years of Follow-up. Allergy Asthma Immunol Res. 2017;9(4):368–372. https://doi.org/10.4168/aair.2017.9.4.368.; Valverde-Monge M, Sánchez-Carrasco P, Betancor D, Barroso B, Rodrigo-Muñoz JM, Mahillo-Fernández I et al. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients. Arch Bronconeumol. 2024;60(1):23–32. https://doi.org/10.1016/j.arbres.2023.11.011.
-
13Academic Journal
Authors: V. V. Naumova, E. К. Beltyukov, О. P. Kovtun, G. A. Bykova, V. I. Troshina, A. N. Mineeva, В. В. Наумова, Е. К. Бельтюков, О. П. Ковтун, Г. A. Быкова, В. И. Трошина, А. Н. Минеева
Source: Meditsinskiy sovet = Medical Council; № 9 (2024); 74-86 ; Медицинский Совет; № 9 (2024); 74-86 ; 2658-5790 ; 2079-701X
Subject Terms: дупилумаб, targeted therapy, genetically engineered biological drugs, omalizumab, dupilumab, таргетная терапия, генно-инженерные биологические препараты, омализумаб
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8334/7354; Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341(26):1966–1973. https://doi.org/10.1056/NEJM199912233412603.; Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. https://doi.org/10.1111/j.1398-9995.2004.00772.x.; Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66(5):671–678. https://doi.org/10.1111/j.1398-9995.2010.02522.x.; Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011;27(11):2223–2228. https://doi.org/10.1185/03007995.2011.620950.; Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486–2496. https://doi.org/10.1056/NEJMoa1804092.; Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018;378(26):2475–2485. https://doi.org/10.1056/NEJMoa1804093.; Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11–25. https://doi.org/10.1016/S2213-2600(21)00322-2.; Canonica GW, Bartezaghi M, Marino R, Rigoni L. Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA - an observational, 2 phase, patient reported outcomes study. Clin Mol Allergy. 2015;13(1):10. https://doi.org/10.1186/s12948-015-0019-7.; Solidoro P, Patrucco F, de Blasio F, Brussino L, Bellocchia M, Dassetto D et al. Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study. Ther Adv Respir Dis. 2019;13:1753466619841274. https://doi.org/10.1177/1753466619841274.; Humbert M, Bourdin A, Taillé C, Kamar D, Thonnelier C, Lajoinie A et al. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J. 2022;60(5):2103130. https://doi.org/10.1183/13993003.03130-2021.; Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, De Blay F et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. https://doi.org/10.1111/cea.13614.; Renner A, Marth K, Patocka K, Idzko M, Pohl W. Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics. Immun Inflamm Dis. 2021;9(3):624–627. https://doi.org/10.1002/iid3.434.; Carpagnano GE, Scioscia G, Buonamico E, Lacedonia D, Diaferia F, Capozza E et al. Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management. Multidiscip Respir Med. 2022;17(1):797. Available at: https://www.researchgate.net/publication/358359986_Early_effectiveness_of_type-2_severe_asthma_treatment_with_dupilumab_in_a_real-life_setting_a_FeNO-driven_choice_that_leads_to_winning_management.; Hoshino M, Akitsu K, Kubota K, Ohtawa J. Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis. Allergol Int. 2022;71(4):490–497. https://doi.org/10.1016/j.alit.2022.05.010.; Pose K, Laorden D, Hernández N, Villamañán E, Quirce S, Domínguez-Ortega J. Efficacy of Dupilumab for Severe Atopic Dermatitis Co-occurring With Asthma in a Real-World Setting. J Investig Allergol Clin Immunol. 2023;33(3):217–219. https://doi.org/10.18176/jiaci.0837.; Minagawa S, Araya J, Watanabe N, Fujimoto S, Watanabe J, Hara H et al. Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP. BMC Pulm Med. 2022;22(1):258. https://doi.org/10.1186/s12890-022-02046-3.; Cabon Y, Molinari N, Marin G, Vachier I, Gamez AS, Chanez P, Bourdin A. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47(1):129–138. https://doi.org/10.1111/CEA.12853.; Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20(1):179. https://doi.org/10.1186/S12931-019-1138-3.; Henriksen DP, Bodtger U, Sidenius K, Maltbaek N, Pedersen L, Madsen H et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis. Eur Clin Respir J. 2018;5(1):1536097. https://doi.org/10.1080/20018525.2018.1536097.; Ramonell RP, Iftikhar IH. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis. Lung. 2020;198(1):95–103. https://doi.org/10.1007/S00408-019-00310-8.; Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200. https://doi.org/10.1016/J.JACI.2018.08.031.; He LL, Zhang L, Jiang L, Xu F, Fei DS. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A pairwise and Bayesian network meta-analysis. Int Immunopharmacol. 2018;64:223–231. https://doi.org/10.1016/J.INTIMP.2018.08.031.; Calzetta L, Matera MG, Rogliani P. Monoclonal antibodies in severe asthma: is it worth it? Expert Opin Drug Metab Toxicol. 2019;15(6):517–520. https://doi.org/10.1080/17425255.2019.1621837.; Nagase H, Suzukawa M, Oishi K, Matsunaga K. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int. 2023;72(1):11–23. https://doi.org/10.1016/j.alit.2022.11.008.; Ito A, Miyoshi S, Toyota H, Suzuki Y, Uehara Y, Hattori S et al. The overlapping eligibility for bioligics in patients with severe asthma and phenotypes. Arerugi. 2022;71(3):210–220. https://doi.org/10.15036/arerugi.71.210.; Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma. 2018;55(2):152–160. https://doi.org/10.1080/02770903.2017.1322611.; Kimura Y, Suzukawa M, Inoue N, Imai S, Akazawa M, Matsui H. Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use. World Allergy Organ J. 2021;14(11):100600. https://doi.org/10.1016/j.waojou.2021.100600.; Akenroye A, Marshall J, Simon AL, Hague C, Costa R, Jamal-Allial A et al. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations. J Allergy Clin Immunol Pract. 2024;S2213-2198(24)00211–3. https://doi.org/10.1016/j.jaip.2024.02.034.; Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. https://doi.org/10.1016/j.jaci.2019.12.006.; Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. MedGenMed. 2005;7(1):27. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1681435/.; Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E. Two decades with omalizumab: what we still have to learn. Biologics. 2018;12:135–142. https://doi.org/10.2147/BTT.S180846.; Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11(12):958–972. https://doi.org/10.1038/nrd3792.; Manuyakorn W, Howarth PH, Holgate ST. Airway remodelling in asthma and novel therapy. Asian Pac J Allergy Immunol. 2013;31(1):3–10. Available at: https://pubmed.ncbi.nlm.nih.gov/23517388.; Akenroye AT, Segal JB, Zhou G, Foer D, Li L, Alexander GC et al. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol. 2023;151(5):1269–1276. https://doi.org/10.1016/j.jaci.2023.01.020.; Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1–12. https://doi.org/10.1016/j.jaci.2019.05.031.; Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–323. https://doi.org/10.1164/rccm.200906-0896OC.; Mansur AH, Gonem S, Brown T, Burhan H, Chaudhuri R, Dodd JW et al. Biologic therapy practices in severe asthma; outcomes from the UK Severe Asthma Registry and survey of specialist opinion. Clin Exp Allergy. 2022;53(2):173–185. https://doi.org/10.1111/cea.14222.; Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021;160(3):814–830. https://doi.org/10.1016/j.chest.2021.04.013.; Baan EJ, de Roos EW, Engelkes M, de Ridder M, Pedersen L, Berencsi K et al. Characterization of Asthma by Age of Onset: A Multi-Database Cohort Study. J Allergy Clin Immunol Pract. 2022;10(7):1825–1834. https://doi.org/10.1016/j.jaip.2022.03.019.; Deschildre A, Marguet C, Langlois C, Pin I, Rittié JL, Derelle J et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856–859. https://doi.org/10.1183/09031936.00008115.; Licari A, Castagnoli R, Denicolò C, Rossini L, Seminara M, Sacchi L et al. Omalizumab in Childhood Asthma Italian Study Group. Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience. Curr Respir Med Rev. 2017;13(1):36–42. https://doi.org/10.2174/1573398X13666170426094536.; Milger K, Korn S, Feder C, Fuge J, Mühle A, Schütte W et al. Criteria for evaluation of response to biologics in severe asthma – the Biologics Asthma Response Score (BARS). Pneumologie. 2023;77:220–232. https://doi.org/10.1055/a-2102-8128.; Milger K, Suhling H, Skowasch D, Holtdirk A, Kneidinger N, Behr J et al. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort. J Allergy Clin Immunol Pract. 2023;11(9):2701–2712. https://doi.org/10.1016/j.jaip.2023.05.047.
-
14Academic Journal
Authors: V. V. Naumova, E. К. Beltyukov, K. A. Zykov, О. P. Kovtun, T. S. Lepeshkova, O. G. Smolenskaya, G. A. Bykova, V. I. Troshina, A. N. Mineeva, В. В. Наумова, Е. К. Бельтюков, К. А. Зыков, О. П. Ковтун, Т. С. Лепешкова, О. Г. Смоленская, Г. А. Быкова, В. И. Трошина, А. Н. Минеева
Source: Meditsinskiy sovet = Medical Council; № 20 (2024); 40-50 ; Медицинский Совет; № 20 (2024); 40-50 ; 2658-5790 ; 2079-701X
Subject Terms: бенрализумаб, targeted therapy, genetically engineered biological drugs, benralizumab, таргетная терапия, генно-инженерные биологические препараты
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8763/7696; Zhang JY, Wenzel SE. Tissue and BAL based biomarkers in asthma. Immunol Allergy Clin North Am. 2007;27:623-632. https//doi.org/10.1016/j.iac.2007.09.003.; Perez-de-Llano L, Tran T, Al-ahmad M, Alacqua M, Bulathsinhala L, Busby J et al. Characterization of eosinophilic and non-eosinophilic severe asthma phenotypes and proportion of patients with these phenotypes in the International Severe Asthma Registry (ISAR). Am J Respir Crit Care Med. 2020;201(C21):1-2. https://doi.10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A4525.; Price D, Wilson AM, Chisholm A, Rigazio A, Burden A, Thomas M, King C. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1-12. https://doi.org/10.2147/jaa.s97973.; Talini D, Novelli F, Bacci E, Bartoli M, Cianchetti S, Costa F et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open. 2015;5(1):e005748. https://doi.org/10.1136/bmjopen-2014-005748.; Belda J, Parameswaran K, Lemiere C, Kamada D, O'Byrne PM, Hargreave FE. Predictors of loss of asthma control induced by corticosteroid withdrawal. Can Respir J. 2006;13(3):129-133. https://doi.org/10.1155/2006/189127.; Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344-1353.e2. https://doi.org/10.1016/j.jaci.2010.04.004.; Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21-29. https://doi.org/10.1016/j.rmed.2016.01.003.; Juniper EF, Svensson K, Mork AC, Stahl E. Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older. Health Qual Life Outcomes. 2005;3:58. https://doi.org/10.1186/1477-7525-3-58.; Tan LD, Bratt JM, Godor D, Louie S, Kenyon NJ. Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy. 2016;9:71-81. https://doi.org/10.2147/jaa.s78049.; Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor a monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14-20. https://doi.org/10.1016/j.ajem.2014.09.036.; Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010;125(6):1237-1244.e2. https://doi.org/10.1016/j.jaci.2010.04.005.; Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW et al. Benralizumab, an anti-interleukin 5 receptor a monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879-890. https://doi.org/10.1016/s2213-2600(14)70201-2.; Milger K, Korn S, Feder C, Fuge J, Muhle A, Schutte W et al. Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS). Pneumologie. 2023;77(4):220-232. https://doi.org/10.1055/a-2014-4350.; FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M et al. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-2141. https://doi.org/10.1016/s0140-6736(16)31322-8.; Chung Y, Katial R, Mu F, Cook EE, Young J, Yang D et al. Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study. Ann Allergy Asthma Immunol. 2022;128(6):669-676.e6.; Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH et al. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. Eur Respir J. 2024;64(1):2301521. https://doi.org/10.1183/13993003.01521-2023.; Basagana M. Martinez-Rivera C, Padro C, Garcia-Olive I, Martinez-Colls M, Navarro J et al. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis. Ann Med. 2024;56(1):2317356. https://doi.org/10.1080/07853890.2024.2317356.; Pelaia C, Busceti MT, Vatrella A, Rago GF, Crimi C, Terracciano R, Pelaia G. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulm Pharmacol Ther. 2019;58:101830. https://doi.org/10.1016/j.pupt.2019.101830.; Sposato B, Scalese M, Camiciottoli G, Carpagnano GE, Pelaia C, Santus P et al. Severe asthma and long-term Benralizumab effectiveness in real-life. Eur Rev Med Pharmacol Sci. 2022;26(20):7461-7473. https://doi.org/10.26355/eurrev_202210_30016.; Martinez-Moragon E, Chiner E, Suliana Mogrovejo A, Palop Cervera M, Lluch Tortajada I, Boira Enrique I, Sanchez Vera AF. Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma. J Asthma. 2024;61(10):1190-1204. https://doi.org/10.1080/02770903.2024.2332351.; Григорьева ЕВ. Региональный опыт терапии тяжелой бронхиальной астмы препаратом бенрализумаб в Республике Бурятия. Вестник Бурятского государственного университета. Медицина и фармация. 2023;(2):9-18. https://doi.org/10.18101/2306-1995-2023-2-9-18.; Phinyo P, Krikeerati T, Vichara-Anont I, Thongngarm T. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis. J Allergy Clin Immunol Pract. 2024;12(2):409-420. https://doi.org/10.1016/j.jaip.2023.11.007.; Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting e2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-2127. https://doi.org/10.1016/s0140-6736(16)31324-1.; Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51(6):836-844. https://doi.org/10.1111/cea.13852.; Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149(4):1309-1317.e12. https://doi.org/10.1016/j.jaci.2021.08.030.; Lombardo N, Pelaia C, Ciriolo M, Della Corte M, Piazzetta G, Lobello N et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol. 2020;34:2058738420950851. https://doi.org/10.1177/2058738420950851.; Katial R, Siddiqui S, Barker P, Kwiatek J. P109 clinical efficacy characterization of benralizumab for patients with nasal polyposis and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol. 2019;123(5):S26. https://doi.org/10.1016/j.anai.2019.08.251.; Watanabe H, Shirai T, Hirai K, Akamatsu T, Nakayasu H, Tamura K et al. Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients. J Asthma. 2022;59(9):1796-1804. https://doi.org/10.1080/02770903.2021.1963769.
-
15Academic Journal
Authors: A. O. Bobkova, A. M. Lila, A. E. Karateev, А. О. Бобкова, А. М. Лила, А. Е. Каратеев
Contributors: The article was prepared within the framework of the basic research topic FURS-2022-008, government contract №1021051503137-7., Статья подготовлена в рамках фундаментальной темы FURS-2022-008, номер государственного задания 1021051503137-7.
Source: Modern Rheumatology Journal; Том 18, № 4 (2024); 16-22 ; Современная ревматология; Том 18, № 4 (2024); 16-22 ; 2310-158X ; 1996-7012
Subject Terms: переключение терапии, biologic disease-modifying antirheumatic drugs, Janus kinase inhibitors, switching therapy, генно-инженерные биологические препараты, ингибиторы Янус-киназ
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1616/1492; https://mrj.ima-press.net/mrj/article/view/1616/1507; Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научнопрактическая ревматология. 2018; 56(3):263-271.; Галушко ЕА, Гордеев АВ, Матьянова ЕВ и др. Труднолечимый ревматоидный артрит в реальной клинической практике. Предварительные результаты. Терапевтический архив. 2022;94(5):661-666.; Бобкова АО, Лила АМ. Проблема переключений генно-инженерных биологических препаратов и ингибиторов Янус-киназ у пациентов с ревматоидным артритом. Современная ревматология. 2023; 17(3):82-88. doi:10.14412/1996-7012-2023-3-82-88; Гордеев АВ, Олюнин ЮА, Галушко ЕА и др. Труднолечимый ревматоидный артрит. Какой он? Современная ревматология. 2021;15(5):7-11. doi:10.14412/1996-7012-2021-5-7-11; Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-35. doi:10.1136/annrheumdis2020-217344. Epub 2020 Oct 1.; Smolen JS. Treat to Target in Rheumatology: A Historical Account on Occasion of the 10th Anniversary. Rheum Dis Clin North Am. 2019 Nov;45(4):477-485. doi:10.1016/j.rdc.2019.07.001. Epub 2019 Aug 16.; Rubbert-Roth A, Szabу MZ, Kedves M, et al. Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019 Dec;18(12):102398. doi:10.1016/j.autrev.2019.102398. Epub 2019 Oct 19.; Каратеев АЕ, Лила АМ, Паневин ТС и др. Динамика показателей, оцениваемых самим пациентом, при использовании различных генно-инженерных биологических препаратов при ревматоидном артрите. Научно-практическая ревматология. 2022;60(4):427-437.; Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration. Ann Rheum Dis. 2022 Oct;81(10):1358-1366. doi:10.1136/annrheumdis-2022-222586. Epub 2022 Jun 15.; Alten R, Burmester GR, Matucci-Cerinic M, et al. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients. Rheumatol Ther. 2023 Dec;10(6):1575-1595. doi:10.1007/s40744-023-00597-3. Epub 2023 Sep 27.; Pappas DA, St John G, Etzel CJ, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2021 Jan;80(1):96-102. doi:10.1136/annrheumdis-2020-217209. Epub 2020 Jul 21.; Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 Feb 8:4:18001. doi:10.1038/nrdp.2018.1.; Kim MJ, Park JW, Lee SK, et al. Treatment Sequence After Initiating Biologic Therapy for Patients With Rheumatoid Arthritis in Korea: A Nationwide Retrospective Cohort Study. J Rheum Dis. 2023 Jan 1;30(1):26-35. doi:10.4078/jrd.22.0024. Epub 2022 Aug 30.; Taylor PC, Matucci Cerinic M, et al. Managing inadequate response to initial antiTNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis. 2022 Aug 16:14:1759720X221114101. doi:10.1177/1759720X221114101.eCollection 2022.; Zhao SS, Kearsley-Fleet L, Bosworth A, et al. Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis. Rheumatology (Oxford). 2022 Nov 28;61(12):4678-4686. doi:10.1093/rheumatology/keac190.; Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2010 May;22(3):321-9. doi:10.1097/BOR.0b013e328337bd01.; Karpes Matusevich AR, Duan Z, Zhao H, et al. Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies. Arthritis Care Res (Hoboken). 2021 Oct; 73(10):1461-1469. doi:10.1002/acr.24358. Epub 2021 Aug 26.; Ebina K, Hirano T, Maeda Y, et al. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis – the ANSWER cohort study. Clin Rheumatol. 2020 Sep;39(9):2563-2572. doi:10.1007/s10067-020-05015-5. Epub 2020 Mar 11.; Fujii T, Murata K, Onizawa H, et al. Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort. Arthritis Res Ther. 2024 Jan 9;26(1):16. doi:10.1186/s13075-023-03251-z.; Conran C, Kolfenbach J, Kuhn K, et al. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management. Curr Rheumatol Rep. 2023 Dec;25(12):285-294. doi:10.1007/s11926-023-01117-6.; Watanabe R, Okano T, Gon T, et al. Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems. Front Med (Lausanne). 2022 Oct 24:9:1049875. doi:10.3389/fmed.2022.1049875.eCollection 2022.; Roodenrijs NMT, Welsing PMJ, van Roon J, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology (Oxford). 2022 Aug 30;61(9):3552-3566. doi:10.1093/rheumatology/keac114.; Jung JY, Lee E, Kim JW, et al. Unveiling difficult-to-treat rheumatoid arthritis: longterm impact of biologic or targeted synthetic DMARDs from the KOBIO registry. Arthritis Res Ther. 2023 Sep 19;25(1):174. doi:10.1186/s13075-023-03165-w.; Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022 Mar 1;24(1): 61. doi:10.1186/s13075-022-02744-7.; Garcia-Salinas R, Sanchez-Prado E, Mareco J, et al. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations. Rheumatol Int. 2023 Oct; 43(10):1821-1828. doi:10.1007/s00296-023-05349-8. Epub 2023 Jun 3.; Edgerton C, Frick A, Helfgott S, et al. Real-World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First-Line Tumor Necrosis Factor Inhibitor Therapy in the United States. ACR Open Rheumatol. 2024 Apr;6(4):179-188. doi:10.1002/acr2.11646. Epub 2024 Jan 14.; Bertsias A, Flouri ID, Repa A, et al. Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis. RMD Open. 2024 Jan 19; 10(1):e003808. doi:10.1136/rmdopen-2023-003808.
-
16Academic Journal
Authors: N. V. Chichasova, A. M. Lila, Н. В. Чичасова, А. М. Лила
Source: Modern Rheumatology Journal; Том 18, № 4 (2024); 106-114 ; Современная ревматология; Том 18, № 4 (2024); 106-114 ; 2310-158X ; 1996-7012
Subject Terms: переносимость, baricitinib, biologic disease-modifying antirheumatic drugs, efficacy, tolerability, барицитиниб, генно-инженерные биологические препараты, эффективность
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1628/1504; Nash P, Kerschbaumer A, Dorner T, et al. Points to consider for the treatment of immunemediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021 Jan;80(1):71-87. doi:10.1136/annrheumdis-2020-218398. Epub 2020 Nov 6.; Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study. Ann Rheum Dis. 2017 Jan;76(1):88-95. doi:10.1136/annrheumdis-2016-210094. Epub 2016 Sep 29.; Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017 Feb 16;376(7):652-662. doi:10.1056/NEJMoa1608345.; Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017 Mar;69(3):506-517. doi:10.1002/art.39953. /N; Genovese MC, Kremer J, Zamani O, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med. 2016 Mar 31;374(13):1243-52. doi:10.1056/NEJMoa1507247.; Smolen J, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi:10.1136/ard-2022-223356. Epub 2022 Nov 10.; Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020 Jun;2(6): e347-e357. doi:10.1016/S2665-9913(20)30032-1.; Taylor PC, Laedermann C, Alten R, et al. A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. J Clin Med. 2023 Jul 6;12(13):4527. doi:10.3390/jcm12134527.; Van der Heijde D, Kartman CE, Xie L, et al. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis – a comprehensive review. Arthritis Res Ther. 2021 Jan 4;23(1):3. doi:10.1186/s13075-020-02379-6.; Caporali R, Aletaha D, Sanmartн R, et al. POS0701 Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: Results from RA-beyond up to 7 years of treatment. Ann Rheum Dis. 2022;81(Suppl.1): 630–631. doi:10.1136/annrheumdis-2022-eular.4546; Emery P, Tanaka Y, Cardillo T, et al. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. Arthritis Res Ther. 2020 May 15; 22(1):115. doi:10.1186/s13075-020-02199-8.; Fraenkel L, Bathon JM, Bryant R, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939. doi:10.1002/acr.24596. Epub 2021 Jun 8.; Takeuchi T, Genovese MC, Haraoui B, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: Results of a prospective study. Ann Rheum Dis. 2019 Feb;78(2):171-178. doi:10.1136/annrheumdis-2018-213271. Epub 2018 Sep 7.; Alten R, Burmester GR, Edwards CE, et al. POS0848. Discontinuation and effectiveness of baricitinib in rheumatoid arthritis according to patient age and prior treatment: 2-year data from the European cohort of the RA-BE-REAL study. Ann Rheum Dis. 2023; 82(suppl1):724-725. doi:10.1136/annrheumdis-2023-eular.2554; Voshaar MO, Klooster PT, Tedjo D, et al. Baricitinib versus TNF-inhibitors in patients with active rheumatoid arthritis and an inadequate response to csDMARDS: 12 weeks results of a pragmatic, multicenter, open label, noninferiority trial. Ann Rheum Dis. 2023; 82(Suppl 1):713. doi:10.1136/annrheumdis2023-eular.4317; Edwards CJ, Mount J, Meeks A, et al. Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data. Rheumatology (Oxford). 2023 Oct 3;62(10): 3400-3408. doi:10.1093/rheumatology/kead074.; Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAKpot’ collaboration. Ann Rheum Dis. 2022 Oct;81(10):1358-1366. doi:10.1136/annrheumdis-2022-222586. Epub 2022 Jun 15.; Aymon R, Mongin D, Bergstra SA, et al. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study). Ann Rheum Dis. 2024 Mar 12;83(4):421-428. doi:10.1136/ard-2023-224670.; Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022 Jan 27;386(4):316-326. doi:10.1056/NEJMoa2109927.; Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis. 2023 Jan;82(1):119-129. doi:10.1136/ard-2022-222259. Epub 2022 Sep 22.; Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi:10.1136/ard-2022-223715. Epub 2023 Mar 17.; Aymon R, Mongin D, Bergstra SA, et al. Incidence of mayor adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK-inhibitors compared to bDMARDs: data from an international collaboration of registries (the “JAK-POT” study). Ann Rheum Dis. 2023;82(Suppl 1): 143-145. doi:10.1136/annrheumdis-2023-eular.660; Meissner Y, Albrecht R, Kekow J, et al. Risk of cardiovascular events under Janus kinase inhibitors in patients with rheumatoid arthritis: observational data from the German RABBIT register. Ann Rheum Dis. 2022; 81(Suppl 1):86-87. Doi:10.1136/annrheumdis-2022-eular.779.; Hoisnard L, Vegas P, Dray-Pira R, et al. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2023 Feb;82(2): 182-188. doi:10.1136/ard-2022-222824. Epub 2022 Oct 5.; Barbulescu A, Askling J, Chatzidionysiou K, et al. Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology (Oxford). 2022 Oct 6;61(10):3952-3962. doi:10.1093/rheumatology/keac068.; Gilbert B, Courvoisier D, Mongin D, et al. Real world effectiveness of baricitinib in the Swiss rheumatoid arthritis register (SCOM-RA). Ann Rheum Dis. 2021;80(Suppl 1):577-578. doi:10.1136/annrheumdis-2021-eular.1781.; Guidelli GM, Viapiana O, Luciano N, et al. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study. Clin Exp Rheumatol. 2021 Jul-Aug;39(4):868-873. doi:10.55563/clinexprheumatol/pudtpo. Epub 2020 Dec 18.; Takagi M, Atsumi T, Matsuno H, et al. Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. Mod Rheumatol. 2023 Jul 4;33(4):647-656. doi:10.1093/mr/roac089.; Pope JE, Fleischmann RM. Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis? Ann Rheum Dis. 2023 Feb;82(2): 161-163. doi:10.1136/ard-2022-223071. Epub 2023 Jan 6.; Pombo-Suarez M, Sanchez-Piedra C, Gomez-Reino J, et al. After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries. Ann Rheum Dis. 2023 Feb;82(2): 175-181. doi:10.1136/ard-2022-222835. Epub 2022 Sep 13.; Perrone V, Losi S, Rogai V, et al. Realworld analysis of therapeutic patterns in patients affected by rheumatoid arthritis in Italy: a focus on baricitinib. Rheumatol Ther. 2020 Sep;7(3):657-665. doi:10.1007/s40744-02-00218-3. Epub 2020 Jul 18.; Perrone V, Losi S, Rogai V, et al. Treatment patterns and pharmacoutilization in patients affected by rheumatoid arthritis in Italian settings. Int J Environ Res Public Health. 2021 May 26;18(11):5679. doi:10.3390/ijerph18115679.; Littlejohn G, Smith T, Tymms K, et al. THU0209 Uptake of Janus kinase inhibitors for management of rheumatoid arthritis in Australia. Ann Rheum Dis. 2020;79(Suppl 1):329. Doi:10.1136/annrheumdis-2020-eular.5055.; Egeberg A, Rosenø NAL, Aagaard D, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis — a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022 Apr:53:151979. doi:10.1016/j.semarthrit.2022.151979. Epub 2022 Feb 9.; Gilbert B, Courvoisier D, Mongin D, et al. POS0668 Real world effectiveness of baricitinib in the Swiss Rheumatoid Arthritis Register (SCQM-RA). Ann Rheum Dis. 2021;80 (Suppl 1):577–578. doi:10.1136/annrheumdis-2021-eular.1781.; Takahashi N, Asai S, Kobayakawa T, et al. Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: Data from a Japanese multicenter registry. Sci Rep. 2020 Dec 14; 10(1):21907. doi:10.1038/s41598-020-78925-8.; https://acrabstracts.org/abstract/a-multinational-prospective-observational-study-inpatients-with-rheumatoid-arthritis-receivingbaricitinib-targeted-synthetic-or-biologicdisease-modifying-therapies-6-month-effectiveness-and-pat/; Page J, Kearsley-Fleet L, Davies R, et al. AB0434 Early experience with JAK inhibitor prescribing in the uk: results from the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis (BSRBR-RA). Ann Rheum Dis. 2019;78(Suppl 2):1680. doi:10.1136/annrheumdis-2019-eular.508.; Rosas J, Senabre-Gallego JM, Soler GS, et al. AB0442 Response to baricitinib in patients with rheumatoid arthritis with failure to conventional synthetic DMARD and/or biological DMARD: data from a local registry. Ann Rheum Dis. 2019;78 (Suppl 2):1684. doi:10.1136/annrheumdis-2019-eular. 3820.; Ciciriello S, Littlejohn G, Treuer T, et al. Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set. ACR Open Rheumatol. 2023 Jul;5(7):345-353. doi:10.1002/acr2.11577. Epub 2023 Jun 12.; Hernandez-Cruz B, Kiltz U, Avouac J, et al. Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis. Rheumatol Ther. 2023 Dec;10(6):1417-1457. doi:10.1007/s40744-023-00591-9. Epub 2023 Sep 16.; Alten R, Burmester GR, Matucci Cerinic M, et al. POS0666 A multinational, prospective, observational study in patients with rheumatoid arthritis receiving baricitinib, targeted synthetic or biologic disease-modifying therapies: 12 month time to discontinuation, effectiveness and patient reported outcome data from the European cohort. Ann Rheum Dis. 2022;81(Suppl 1):606–607. doi:10.1136/annrheumdis-2022-eular.265.; Baldi C, Falsetti P, Conticini E, et al. POS0661 Rapid response to baricitinib in patients with rheumatoid arthritis and an inadequate response to methotrexate and at least one biologic DMARD: a clinical and power doppler ultrasound study. Ann Rheum Dis. 2021;80(Suppl 1):573. doi10.1136/annrheumdis-2021-eular.1007.; Taylor PC, Lee YC, Fleischmann R, et al. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. J Clin Med. 2019 Jun 12;8(6):831. doi:10.3390/jcm8060831.; Deprez V, Le Monnier L, Sobhy-Danial JM, et al. Therapeutic maintenance of baricitinib and tofacitinib in real life. J Clin Med. 2020 Oct 16;9(10):3319. doi:10.3390/jcm9103319.; Torikai E, Suzuki D. THU0196 Efficacy and safety up to 24 weeks of baricitinib for Japanese patients with rheumatoid arthritis in real world multicenter clinical data. Ann Rheum Dis. 2019;78(Suppl 2):375-6. doi:10.1136/annrheumdis-2019-eular.4496; Cometi L, Bruni C, Tofani L, et al. AB0256 Baricitinib (BARI) versus biologics impact on steroid tapering in rheumatoid arthritis (RA). Ann Rheum Dis. 2021;80(Suppl 1): 1154-5. doi:10.1136/annrheumdis-2021-eular. 1343.; Yoshii I, Sawada N, Chijiwa T. AB0383 Comparison of efficacy and safety in jak inhibitor due to a difference of selectivity — tofacitinib vs baricitinib. Ann Rheum Dis. 2022;81(Suppl 1):1318-1319. doi:10.1136/annrheumdis-2022-eular.129; Torikai E, Hirano Y, Suzuki D, Kanayama Y. FRI0137 Discontinuation of baricitinib after achieving low disease activity in patients with rheumatoid arthritis in clinical practice; a multicenter observational study. Ann Rheum Dis. 2020;79(Suppl 1):651. doi:10.1136/annrheumdis-2020-eular.1546.; Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010 Apr;69(4):631-7. doi:10.1136/ard.2009.123919. Epub 2010 Mar 9.; Sepriano A, van Dijk B, Ramiro S, et al. Distinction and prognosis of early arthritis phenotypes: an analysis in three European cohort. RMD Open. 2023 Nov;9(4):e003611. doi:10.1136/rmdopen-2023-003611.; Lopez-Romero P, de la Torre I, Haladyj E, et al. Baricitinib further enhances diseasemodifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2022 May;81(5):622-631. doi:10.1136/annrheumdis-2021-221323. Epub 2022 Feb 22.
-
17Academic Journal
Authors: A. M. Lila, T. V. Dubinina, D. G. Tolkacheva, K. V. Sapozhnikov, N. A. Sableva, M. A. Morozova, P. S. Pukhtinskaia, А. М. Лила, Т. В. Дубинина, Д. Г. Толкачева, К. В. Сапожников, Н. А. Саблева, М. А. Морозова, П. С. Пухтинская
Contributors: The article was sponsored by BIOCAD JSC, Статья спонсируется компанией АО «БИОКАД»
Source: Modern Rheumatology Journal; Том 18, № 2 (2024); 33-40 ; Современная ревматология; Том 18, № 2 (2024); 33-40 ; 2310-158X ; 1996-7012
Subject Terms: скорректированное непрямое сравнение, ankylosing spondylitis, biologic disease-modifying antirheumatic drugs, seniprutug (BCD-180), adalimumab, systematic review, matching-adjusted indirect comparison, анкилозирующий спондилит, генно-инженерные биологические препараты, сенипрутуг (BCD-180), адалимумаб, систематический обзор
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1559/1455; Ramiro S, Nikiphorou E, Sepriano A, et al.ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34. doi:10.1136/ard-2022-223296. Epub 2022 Oct 21.; Румянцева ДГ, Эрдес ШФ. Аксиальныйспондилоартрит: современный взгляд на концепцию и эволюцию болезни. Современная ревматология. 2019;13(4):4-10. doi: 10/14412/1996-7012-2019-4-4-10.; Лила АМ, Дубинина ТВ, Древаль РО и др. Медико-социальная значимость и расчет экономического бремени аксиального спондилоартрита в Российской Федерации. Современная ревматология. 2022;16(1):20-25. doi:10.14412/1996-7012-2022-1-20-25.; Yi E, Ahuja A, Rajput T, et al. Clinical, economic, and humanistic burden associated with delayed diagnosis of axial spondyloarthritis: a systematic review. Rheumatol Ther. 2020; 7:65–87. doi:10.1007/s40744-020-00194-8.; Poddubnyy D. Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. Rheumatology (Oxford). 2020 Oct 1;59(Suppl4):iv6-iv17. doi:10.1093/rheumatology/keaa250.; Juanola X, Ramos MJM, Belzunegui JM, et al. Treatment Failure in Axial Spondyloarthritis: Insights for a Standardized Definition. Adv Ther. 2022 Apr;39(4):1490-1501. doi:10.1007/s12325-022-02064-x. Epub 2022 Feb 24.; Britanova OV, Lupyr KR, Staroverov DB, et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat Med. 2023 Nov;29(11): 2731-2736. doi:10.1038/s41591-023-02613-z. Epub 2023 Oct 23.; Насонов ЕЛ, Мазуров ВИ, Лила АМ и др. Эффективность и безопасность препарата BCD-180, моноклонального антитела к TRBV9+ T-лимфоцитам, у пациентов с активным рентгенологическим аксиальным спондилоартритом: результаты 36 недель рандомизированного двойного слепого плацебо-контролируемого клинического исследования фазы 2 ELEFTA. Научно-практическая ревматология. 2024;62(1):71-86.; Омельяновский ВВ, Авксентьева МВ, Сура МВ и др. Методические рекомендации по проведению непрямых сравнений лекарственных препаратов. Москва: ФГБУ «ЦЭККМП»; 2017. 32 с.; Реброва ОЮ, Горяйнов СВ. Непрямые и смешанные сравнения медицинских технологий, сетевой метаанализ. Медицинские технологии. Оценка и выбор. 2013;(4):8-14.; European Medicines Agency. Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis. 2018. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-axialspondyloarthritis-revision-1_en.pdf; Дубинина ТВ, Гайдукова ИЗ, Соколова ВД и др. Эффективность и безопасность генно-инженерных биологических препаратов для лечения анкилозирующего спондилита: систематический обзор и метаанализ препаратов, зарегистрированных в РФ. Научно-практическая ревматология. 2020;58(6):646-657.; Phillippo D, Ades T, Dias S, et al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. (Technical Support Documents). NICE Decision Support Unit. http://www.nicedsu.org.uk/Populationadjusted-ICs-TSD(3026862).htm; Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal. Med Decis Making. 2018 Feb;38(2):200-211. doi:10.1177/0272989X17725740.; Van der Heijde D, Kivitz A, Schiff MH, et al; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006 Jul;54(7):2136-46. doi:10.1002/art.21913.; Sterne JAC, Savovi J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366: l4898. doi:10.1136/bmj.l4898.; Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012 Sep-Oct; 15(6):940-7. doi:10.1016/j.jval.2012.05.004.; Macfarlane GJ, Pathan E, Jones GT,Dean LE. Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology (Oxford). 2020 Sep 1;59(9): 2481-2490. doi:10.1093/rheumatology/kez657.; Wang R, Dasgupta A, Ward MM. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Netw Open. 2022 Mar 1;5(3):e222312. doi:10.1001/jamanetworkopen.2022.2312.; Yi E, Ahuja A, Rajput T, et al. Clinical, Economic, and Humanistic Burden Associated With Delayed Diagnosis of Axial Spondyloarthritis: A Systematic Review. Rheumatol Ther. 2020 Mar;7(1):65-87. doi:10.1007/s40744-020-00194-8; Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky. Curr Rheumatol Rep. 2018 May 12;20(6):35. doi:10.1007/s11926-018-0744-2.
-
18Academic Journal
Authors: O. N. Egorova, G. M. Tarasova, A. V. Datsina, B. G. Issayeva, D. S. Dilmanova, S. M Issayeva, A. M. Lila, О. Н. Егорова, Г. М. Тарасова, А. В. Дацина, Б. Г. Исаева, Д. С. Дильманова, С. М. Исаева, А. М. Лила
Contributors: The article was prepared within the framework of research work (state assignment № PK 122040400024-7) and international scientific cooperation of V.A. Nasonova Research Institute of Rheumatology (Russia) and the Kazakh National Medical University named after S.D. Asfendiyarov" (Kazakhstan). The investigation has not been sponsored., Статья подготовлена в рамках научно-исследовательской работы (государственное задание № РК 122040400024-7) и международного научного сотрудничества ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» (Россия) и НАО «Казахский национальный медицинский университет им. С.Д. Асфендиярова» (Казахстан). Исследование не имело спонсорской поддержки.
Source: Modern Rheumatology Journal; Том 18, № 5 (2024); 107-115 ; Современная ревматология; Том 18, № 5 (2024); 107-115 ; 2310-158X ; 1996-7012
Subject Terms: авакопан, steroid-sparing therapy, glucocorticoids, immunosuppressants, genetically engineered biological drugs, rituximab, avacopan, стероидсберегающая терапия, глюкокортикоиды, иммунодепрессанты, генно-инженерные биологические препараты, ритуксимаб
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1647/1526; https://mrj.ima-press.net/mrj/article/view/1647/1532; Van Beers JJBC, Vanderlocht J, Roozendaal C, Damoiseaux J. Detection of anti-neutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence. Methods Mol Biol. 2019: 1901:47-62. doi:10.1007/978-1-4939-8949-2_4.; White J, Dubey S. Eosinophilic granulomatosis with polyangiitis: A review. Autoimmun Rev. 2023 Jan;22(1):103219. doi:10.1016/j.autrev.2022.103219. Epub 2022 Oct 22.; Watts RA, Mahr A, Mohammad AJ et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015 Apr:30 Suppl 1:i14-22. doi:10.1093/ndt/gfv022.; Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020 Aug 27;6(1):71. doi:10.1038/s41572-020-0204-y; Mohammad AJ. An update on the epidemiology of ANCA-associated vasculitis. Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii42-iii50. doi:10.1093/rheumatology/keaa089.; Terrier В, Darbon R, Durel СА, et al. French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). Orphanet J Rare Dis. 2020 Dec 29; 15(Suppl 2):351. doi:10.1186/s13023-020-01621-3.; Yates M, Watts AR, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi:10.1136/annrheumdis-2016-209133.; Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 2;83(1): 30-47. doi:10.1136/ard-2022-223764.; Cutolo M, Seriolo B, Pizzorni C, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev. 2008 Dec;8(2):153-5. doi:10.1016/j.autrev.2008.07.010. Epub 2008 Aug 12.; Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020 Aug;16(8):437-447. doi:10.1038/s41574-020-0341-0. Epub 2020 Apr 14.; Patel NJ, Jayne DRW, Merkel PA, et al. The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol. 2023 Jul;5(7):e413-e421. doi:10.1016/S2665-9913(23)00131-5.; Koshi EJ, Young K, Mostales JC, et al. Complications of corticosteroid therapy: a Comprehensive literature review. J Pharm Technol. 2022 Dec; 38 (6):360-367. doi:10.1177/87551225221116266.; Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Therapeut. 2017 Nov;39(11):2216-2229. doi:10.1016/j.clinthera.2017.09.011.; Yao TC, Huang YW, Chang SM, et al. Association between oral corticosteroid bursts and severe adverse events: a Nationwide population-based cohort study. Ann Intern Med. 2020 Sep 1;173(5):325-330. doi:10.7326/M20-0432; Tan JA, Dehghan N, Chen W, et al. Mortality in ANCA-associated vasculitis: ametaanalysis of observational studies. Ann Rheum Dis. 2017 Sep;76 (9):1566-1574. doi:10.1136/annrheumdis-2016-210942.; Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCAassociated vasculitis. Ann Rheum Dis. 2011 Mar;70(3):488-494. doi:10.1136/ard.2010.137778.; McGovern D, Williams SP, Parsons K, et al. Long-term outcomes in elderly patients with ANCA-associated vasculitis. Rheumatology (Oxford). 2020 May 1;59(5):1076-1083. doi:10.1093/rheumatology/kez388.; Rahmattulla C, Berden AE, Wakker SC, et al. Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis diagnosed between 1991 and 2013. Arthritis Rheumatol. 2015 Dec; 67(12):3270-8. doi:10.1002/art.39317.; Bermas BL. Paternal safety of antirheumatic medications. Best Pract Res Clin Obstet Gynaecol. 2020 Apr:64:77-84. doi:10.1016/j.bpobgyn.2019.09.004. Epub 2019 Oct 8.; Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020 Feb 13;382 (7):622-631. doi:10.1056/NEJMoa1803537.; Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021 Jun 1; 325(21):2178-2187. doi:10.1001/jama.2021.6615.; Xiao Y, Guyatt G, Zeng L, et al. Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCAassociated vasculitis: a systematic review. BMJ Open. 2022 Feb 25;12 2):e050507. doi:10.1136/bmjopen-2021-050507.; Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheumatol. 2021 Aug;73(8):1366-1383. doi:10.1002/art.41773. Epub 2021 Jul 8.; Tieu J, Smith R, Basu N, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology (Oxford). 2020 Apr 1;59(4): e24-e32. doi:10.1093/rheumatology/kez640.; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021.; Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015 Jun;74(6):1178-82. doi:10.1136/ annrheumdis-2014-206404. Epub 2015 Mar 4.; Charles P, Perrodeau E, Samson M, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibodyassociated vasculitis: a randomized trial. Ann Intern Med. 2020 Aug 4;173(3):179-187. doi:10.7326/M19-3827. Epub 2020 Jun 2.; Smith RM, Jones RB, Specks U, et al. Rituximab versus azathioprine for maintenance of remission for patients with ANCAassociated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis. 2023 Jul;82(7):937-944. doi:10.1136/ard-2022-223559. Epub 2023 Mar 23.; Magri SJ, Ugarte-Gil MF, Brance ML, et al. Pan American League of Associations for Rheumatology guidelines for the treatment of ANCA-associated vasculitis. Lancet Rheumatol. 2023 Aug;5(8):e483-e494. doi:10.1016/S2665-9913(23)00128-5. Epub 2023 Jul 6.; Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024 Apr;105(4):684-701. doi:10.1016/j.kint.2023.10.016.; Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15;363(3):211-20. doi:10.1056/NEJMoa0909169.; Gerard M, de Boysson H, Morello R, et al. Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy. Scand J Rheumatol. 2023 Mar; 52(2):161-173. doi:10.1080/03009742.2021.2001929. Epub 2022 Jan 20.; Vassilopoulos A, Vassilopoulos S, Kalligeros M, et al. Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: a systematic review and meta-analysis. Front Med (Lausanne). 2023 Mar 1:10:1110548. doi:10.3389/fmed.2023.1110548. eCollection 2023.; Liu L, Lu H, Zou G, et al. Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series. BMC Nephrol. 2023 Feb 8;24(1):28. doi:10.1186/s12882-023-03075-8.; Ishikawa Y, Tokutsu K, Nakayamada S, et al. Short-term effectiveness and safety of rituximab versus cyclophosphamide for lifethreatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database. Ann Rheum Dis. 2024 Jan 2;83(1):103-111. doi:10.1136/ard-2023-224472.; Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of b-cell lymphoid malignancies. BioDrugs. 2011 Feb 1;25(1):13-25. doi:10.2165/11539590-000000000-00000.; Amudala NA, Boukhlal S, Sheridan B, et al. Obinutuzumab as treatment for ANCAassociated vasculitis. Rheumatology (Oxford). 2022 Aug 30;61(9):3814-3817. doi:10.1093/rheumatology/keab916.; Urlaub D, Zhao S, Blank N, et al. Activation of natural killer cells by rituximab in granulomatosis with polyangiitis. Arthritis Res Ther. 2019 Dec 11;21(1):277. doi:10.1186/s13075-019-2054-0; McGovern DP, McClure ME, Coates M, et al; ObiVas Investigators. Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA associated vasculitis: ObiVas. BMJ Open. 2024 Jul 17;14(7): e083277. doi:10.1136/bmjopen-2023-083277.; Do RK, Chen-Kiang S. Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev. 2002 Feb;13(1):19-25. doi:10.1016/s1359-6101(01)00025-9.; Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013 Oct;65(10): 2672-9. doi:10.1002/art.38074.; Jayne D, Blockmans D, Luqmani R, et al. Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study. Arthritis Rheumatol. 2019 Jun;71(6):952-963. doi:10.1002/art.40802. Epub 2019 Apr 16.; McClure ME, Gopaluni S, Wason J, et al. A randomised study of rituximab and belimumab sequential therapy in PR3 ANCAassociated vasculitis (COMBIVAS): design of the study protocol. Trials. 2023 Mar 11;24(1): 180. doi:10.1186/s13063-023-07218-y.; Trivioli G, Vaglio A. The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy. Clin Exp Immunol. 2020 Dec;202(3):403–6. doi:10.1111/cei.13515. Epub 2020 Oct 5.; https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=432014; https://www.ema.europa.eu/en/documents/product-information/tavneosepar-product-information_en.pdf.; Jayne D, Merkel PA, Schall TJ, Bekker P. ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021 Feb 18;384(7):599-609. doi:10.1056/NEJMoa2023386.; Jayne D, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi:10.1681/ASN.2016111179. Epub 2017 Apr 11.; Merkel PA, Niles J, Jimenez R, et al. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020 Nov; 2(11):662-671. doi:10.1002/acr2.11185. Epub 2020 Oct 31.; Cortazar FB, Niles JL, Jayne D, et al. Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan. Kidney Int Rep. 2023 Feb 3; 8(4):860-870. doi:10.1016/j.ekir.2023.01.039. eCollection 2023 Apr.; Cortazar FB, Cerda J, Dhanani R, et al. Avacopan in patients with rapidly progressive glomerulonephritis requiring dialysis. Kidney Int Rep. 2023 May 29;8(8):1687-1691. doi:10.1016/j.ekir.2023.05.017. eCollection 2023 Aug.; Abe Y, Minowa K, Kogami M et al. Avacopan is possibly associated with the improvement of ANCA-associated vasculitis activity without decreasing ANCA titres: a four-case series. Rheumatology (Oxford). 2023 Nov 2; 62(11):e317-e318. doi:10.1093/rheumatology/kead191.; Van Leeuwen JR, Bredewold OW, van Dam LS, et al. Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep. 2021 Dec 8;7(3):624-628. doi:10.1016/j.ekir.2021.11.036. eCollection 2022 Mar.; Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006 Jan;253(1): 98-108. doi:10.1007/s00415-005-0934-5. Epub 2005 Jul 27.; Gopaluni S, Smith R, Goymer D, et al. Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE). Arthritis Res Ther. 2022 Apr 1; 24(1):81. doi:10.1186/s13075-022-02761-6.; Ortiz-Fernandez L, Carmona EG, Kerick M, et al. Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing. Ann Rheum Dis. 2023 Jun;82(6):837-847. doi:10.1136/ard-2022-223697. Epub 2023 Feb 16.; Mettler C, Durel CA, Guilpain P, et al. Off-label use of biologics for the treatment of refractory and/or relapsing granulomatosis with polyangiitis. Eur J Intern Med. 2022 Feb: 96:97-101. doi:10.1016/j.ejim.2021.10.028. Epub 2021 Oct 27.; Langford CA, Monach PA, Specks U, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis. 2014 Jul;73(7):1376-9. doi:10.1136/annrheumdis-2013-204164. Epub 2013 Dec 9.; Kamesh L, Harper L, Savage CO. ANCA-positive vasculitis. J Am Soc Nephrol. 2002 Jul;13(7):1953-60. doi:10.1097/01.asn.0000016442.33680.3e.; Bala MM, Malecka-Massalska TJ, Koperny M, et al. Anti-cytokine targeted therapies for ANCA-associated vasculitis. Cochrane Database Syst Rev. 2020 Sep 29; 9(9):CD008333. doi:10.1002/14651858. CD008333.pub2.; Morgan MD, Drayson MT, Savage CO, Harper L. Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract. 2011;117(2):c89-97. doi:10.1159/000319655. Epub 2010 Aug 6.; Silva F, Seo P, Schroeder DR, et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum. 2011 Aug;63(8):2495-503. doi:10.1002/art.30394.; Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004 Mar;15(3):717-21. doi:10.1097/01.asn.0000114554.67106.28.; Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford). 2002 Nov; 41(11):1303-7. doi:10.1093/rheumatology/41.11.1303.; Kleinert J, Lorenz M, Köstler W, et al. Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr. 2004 May 31;116(9-10):334-8. doi:10.1007/BF03040906.; Laurino S, Chaudhry A, Booth A, et al. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant. 2010 Oct;25(10):3307–3314. doi:10.1093/ndt/gfq187. Epub 2010 Apr 5.; Chen M, Kallenberg CG. ANCA-associated vasculitides – advances in pathogenesis and treatment. Nat Rev Rheumatol. 2010 Nov; 6(11):653-64. doi:10.1038/nrrheum.2010.158. Epub 2010 Oct 5.; Krajewska Wojciechowska J, KoscielskaKasprzak K, Krajewski W, Morawski K. Serum levels of interleukin-32 and interleukin-6 in granulomatosis with polyangiitis and microscopic polyangiitis: association with clinical and biochemical findings. Eur Cytokine Netw. 2019 Dec 1;30(4):151-159. doi:10.1684/ecn.2019.0439.; Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev. 2022 May 13;5(5): CD013484. doi:10.1002/14651858. CD013484.pub3.; Tang PF, Xu LC, Hong WT, Shi HY. Successful treatment of granulomatosis with polyangiitis using tocilizumab combined with glucocorticoids: a case report. World J Clin Cases. 2023 Feb 16;11(5):1144-1151. doi:10.12998/wjcc.v11.i5.1144.; Berti A, Cavalli G, Campochiaro C, et al. Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab. Semin Arthritis Rheum. 2015 Aug;45(1):48-54. doi:10.1016/j.semarthrit.2015.02.002. Epub 2015 Feb 20.; Sakai R, Kondo T, Kikuchi J, et al. Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial. Mod Rheumatol. 2016 Nov;26(6):900-907. doi:10.3109/14397595.2016.1160968. Epub 2016 Apr 21.; Vega Villanueva KL, Espinoza LR. Eosinophilic vasculitis. Curr Rheumatol Rep. 2020 Jan 11;22(1):5. doi:10.1007/s11926-020-0881-2.; Emmi G, Bettiol A, Gelain E, et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023 Jun;19(6):378-393. doi:10.1038/s41584-023-00958-w. Epub 2023 May 9.; Yamane T, Hashiramoto A. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan. Arthritis Res Ther. 2023 Jun 26; 25(1):110. doi:10.1186/s13075-023-03097-5.; Nolasco S, Portacci A, Campisi R, et al. Effectiveness and safety of anti-IL-5/R biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study. Front Immunol. 2023 Jun 30:14: 1204444. doi:10.3389/fimmu.2023.1204444. eCollection 2023.; Wechsler ME, Nair P, Terrier B, et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2024 Mar 7;390(10):911-921. doi:10.1056/NEJMoa2311155. Epub 2024 Feb 23.; Cottu A, Groh M, Desaintjean C, et al. Benralizumab for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2023 Dec; 82(12):1580-1586. doi:10.1136/ard-2023-224624. Epub 2023 Aug 7.; Nanzer AM, Maynard-Paquette AC, Alam V, et al. Long-term effectiveness of benralizumab in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2024 Mar;12(3):724-732. doi:10.1016/j.jaip.2024.01.006. Epub 2024 Jan 9.
-
19
-
20